<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey W Clark, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hanna K Sanoff, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2731716652"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The treatment of metastatic colorectal cancer (mCRC) is evolving. In addition to chemotherapy, many active agents for mCRC have been developed that are associated with improved overall survival. Management is also increasingly being driven by tumor biology and gene expression analysis of individual tumors. (See  <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles", section on 'Predictive biomarkers'</a>.)</p><p>The approach to later lines of systemic therapy for inoperable mCRC is discussed here. General principles of systemic chemotherapy, selection of initial systemic therapy, and other topics related to the management of mCRC are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2512.html" rel="external">"Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status"</a>.)</p><p></p><p class="headingAnchor" id="H2872944625"><span class="h1">AVAILABLE AGENTS AND OVERVIEW OF THE THERAPEUTIC APPROACH</span><span class="headingEndMark"> — </span>There are multiple different classes of drugs with antitumor activity in mCRC:</p><p class="bulletIndent1"><span class="glyph">●</span>Fluoropyrimidines (including <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [FU], which is usually given intravenously with <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> [LV], and the oral agents <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a>, S-1, and tegafur plus uracil [UFT]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">Irinotecan</a>, which is active as monotherapy as well as in combination with other active agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">Oxaliplatin</a>, which is only active when partnered with a second cytotoxic agent, most commonly a fluoropyrimidine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a> and <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>, two monoclonal antibodies (MoAbs) directed against the epidermal growth factor receptor (EGFR), and are only effective for tumors that are <em>RAS</em>/<em>BRAF</em> wild-type. (See <a class="local">'RAS/BRAF wild-type tumors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">Bevacizumab</a>, a MoAb targeting the vascular endothelial growth factor (VEGF), and <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">ramucirumab</a>, a recombinant MoAb of the immunoglobulin G1 (IgG1) class that binds to the VEGF receptor 2 (VEGFR-2), blocking receptor activation. (See <a class="local">'Antiangiogenesis therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>, a recombinant fusion protein consisting of VEGF-binding portions from the human VEGF receptor 1 (VEGFR-1) and VEGFR-2 fused to the Fc portion of human IgG1, functions as a decoy receptor that prevents intravascular and extravascular VEGF-A, VEGF-B, and placenta growth factor (PlGF) from binding to their receptors. (See <a class="local">'Role of aflibercept'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">Regorafenib</a>, an orally active inhibitor of angiogenic tyrosine kinases (including the VEGF receptors 1 to 3), as well as other membrane and intracellular kinases. (See <a class="local">'Regorafenib'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">Fruquintinib</a>, a selective small molecule inhibitor of VEGFR 1, 2, and 3 tyrosine kinases. (See <a class="local">'Fruquintinib'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">Trifluridine-tipiracil</a> (TAS-102), an oral cytotoxic agent that consists of the nucleoside analog <a class="drug drug_general" data-topicid="10021" href="/z/d/drug information/10021.html" rel="external">trifluridine</a> (a cytotoxic antimetabolite that inhibits thymidylate synthase and, after modification within tumor cells, is incorporated into DNA, causing strand breaks) and tipiracil, a potent thymidine phosphorylase inhibitor, which inhibits trifluridine metabolism and has antiangiogenic properties as well. (See <a class="local">'Trifluridine-tipiracil with or without bevacizumab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <em>BRAF</em> inhibitor <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a>, which is approved, in combination with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, for treatment of <em>RAS</em> wild-type, <em>BRAF </em>V600E mutant CRC, after prior therapy. (See <a class="local">'RAS wild-type, BRAF mutated tumors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunotherapy with immune checkpoint inhibitors that target the programmed death receptor 1 (PD-1; ie, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>), with or without immune checkpoint inhibitors that target a different checkpoint, cytotoxic T lymphocyte antigen 4 (CTLA-4, ie, <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>), may be beneficial for advanced high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) mCRC. Despite the tumor-agnostic US Food and Drug Administration (FDA) approval for pembrolizumab in patients with a high tumor mutational burden (TMB), benefit in MMR-proficient CRC with high levels of TMB has not yet been established. (See <a class="local">'MMR-proficient tumors with high tumor mutational burden'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">Larotrectinib</a> and <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a> are tropomyosin receptor kinase (TRK) inhibitors that are approved for treatment of TRK fusion-positive cancers. (See <a class="local">'TRK fusion-positive tumors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human epidermal growth factor receptor 2 (HER2)-overexpressing tumors may respond to treatments targeting HER2, including <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> plus <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a> or <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">lapatinib</a> or the antibody-drug conjugate <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a>. (See <a class="local">'RAS wild-type, HER2 overexpressors'</a> below.)</p><p></p><p>Despite the pace of clinical research, the best way to combine and sequence all of these drugs to optimize treatment is evolving. In general, exposure to all active drugs, as appropriate, is more important than the specific sequence of administration.</p><p class="headingAnchor" id="H191342236"><span class="h2">Multipanel somatic (tumor) and germline genomic testing</span><span class="headingEndMark"> — </span>Increasingly, biomarker expression is driving therapeutic decision-making in treatment of advanced cancer. Gene profiling of tumor tissue and germline genomic testing should be undertaken as quickly as possible after diagnosis of mCRC because of the significant treatment implications, both for initial systemic therapy as well as subsequent treatments. However, biomarkers that identify patients who are candidates for most of the approved agents that are active against mCRC are unknown, with several notable exceptions. (See  <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles", section on 'Predictive biomarkers'</a>.)</p><p>The American Society of Clinical Oncology (ASCO) has issued a provisional clinical opinion that supports somatic and germline genomic testing in metastatic or advanced cancer when there are genomic biomarker-linked therapies approved by regulatory agencies for their cancer [<a href="#rid1">1</a>]. Given the tissue-agnostic approvals for any advanced cancer with a high tumor mutational burden or DNA mismatch repair deficiency (checkpoint inhibitor immunotherapy), or neurotrophic tyrosine receptor kinase (NTRK) fusions (TRK inhibitors), this provides a rationale for testing for all solid tumors, if the individual would be a candidate for these treatments. Testing should also be considered to determine candidacy for targeted therapies approved for other diseases in patients without an approved genomic biomarker-linked therapy; however, off-label/off-study use of such therapies is not recommended when a clinical trial is available, or without evidence of meaningful efficacy in clinical trials. (See <a class="local">'Options for treatment at progression'</a> below.)</p><p>The FDA has approved two gene panel tests (MSK-IMPACT and F1CDx) for analyzing pathogenic changes in solid tumors; these tests can be used on formalin-fixed, paraffin-embedded (FFPE) tissue regardless of the primary organ from which the tumor arose [<a href="#rid2">2-4</a>]. These tests detect pathogenic variations in the coding regions of hundreds of genes. These gene panel tests also provide information about differences between tumor and adjacent noncancerous tissue and about genomic signatures such as MSI, TMB, and the presence of specific mutations/rearrangements for which a molecularly targeted agent may be available, and, in some cases, approved for that patient's individual tumor. Unfortunately, only a minority of patients with mCRC will be found to have truly actionable mutations. (See  <a class="medical medical_review" href="/z/d/html/17039.html" rel="external">"Next-generation DNA sequencing (NGS): Principles and clinical applications", section on 'Cancer screening and management'</a>.)</p><p>The use of circulating tumor DNA (ctDNA) to detect and quantify tumor-specific genetic alterations, including <em>RAS</em> mutations, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles", section on 'What is the role of ctDNA?'</a>.)</p><p class="headingAnchor" id="H1886913175"><span class="h2">Approach to initial therapy</span><span class="headingEndMark"> — </span>Initial chemotherapy for patients with nonoperable disease is generally based upon patient fitness and comorbidity, <em>RAS</em> and <em>BRAF</em> mutation status, the presence of dMMR/MSI-H, the location of the primary tumor, and the intent of therapy. An algorithmic approach to selecting initial therapy based upon these factors is presented in the algorithm  (<a class="graphic graphic_algorithm graphicRef109247" href="/z/d/graphic/109247.html" rel="external">algorithm 1</a>), and specific recommendations, as well as the data supporting this approach are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach"</a>.)</p><p class="headingAnchor" id="H2311972876"><span class="h2">Subsequent treatment and the continuum of care model</span><span class="headingEndMark"> — </span>The approach to subsequent therapy after the initial regimen is variable and might include retreatment with the original regimen on which there was not already disease resistance (eg, if the patient was transitioned to maintenance chemotherapy following an initial period of combination chemotherapy) or a switch to a different regimen altogether because of disease progression or intolerance to the initial regimen. (See  <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles", section on 'Continuous versus intermittent therapy'</a>.)</p><p>For patients with mCRC, the model of distinct "lines" of chemotherapy (in which regimens containing non-cross-resistant drugs are each used in succession until disease progression) has been largely abandoned in favor of a "continuum of care" approach [<a href="#rid5">5</a>]. This approach emphasizes an individualized treatment strategy that might include phases of "maintenance" or lower intensity chemotherapy interspersed with more aggressive treatment protocols, re-challenging patients who initially responded to first-line treatment with the same agents after a period of alternative treatments [<a href="#rid6">6-9</a>], treatment-free intervals, as well as reutilization of previously administered chemotherapy agents in combination with other active drugs.</p><p>An important principle is that exposure to all active drugs during the course of treatment for mCRC, as appropriate, is more important than the specific sequence of drug administration in order to maximize overall survival (OS). The proportion of patients receiving all active agents was correlated strongly with median survival in phase III trials [<a href="#rid5">5,10,11</a>].</p><p class="headingAnchor" id="H3754841301"><span class="h1">OPTIONS FOR TREATMENT AT PROGRESSION</span></p><p class="headingAnchor" id="H2918738614"><span class="h2">Eligible for molecularly targeted therapy</span></p><p class="headingAnchor" id="H2684461198"><span class="h3">Microsatellite unstable/deficient mismatch repair tumors</span><span class="headingEndMark"> — </span>For patients who have high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR) tumors who did not receive an immune checkpoint inhibitor for initial first-line therapy, we suggest immune checkpoint inhibitor immunotherapy rather than another form of systemic therapy. Two options are available:</p><p class="bulletIndent1"><span class="glyph">●</span>Monotherapy with an immune checkpoint inhibitor that targets the programmed cell death 1 (PD-1) receptor, ie, either <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> or <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, is one option. In clinical trials, objective response rates (ORRs) with these two PD-1 inhibitors are 30 to 50 percent, and some responses are durable. Both drugs have been approved by the US Food and Drug Administration (FDA) for this indication in the United States, and the choice of one agent over the other is empiric. Patients who experience disease progression on either of these drugs should not be offered the other.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another option is the combination of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, a monoclonal antibody directed against a different immune checkpoint, cytotoxic T lymphocyte antigen 4 (CTLA-4). Although there are no randomized trials directly comparing dual therapy with monotherapy with either nivolumab or <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> alone, indirect comparisons from the multicohort phase II CheckMate 142 trial suggest that combined immunotherapy provides improved efficacy over anti-PD-1 monotherapy and has a favorable risk-benefit ratio. Updated analyses with long-term follow-up of the two second-line cohorts reported four-year progression-free survival (PFS) of 52 percent in the combination nivolumab-ipilimumab arm and 36 percent with single-agent nivolumab [<a href="#rid12">12</a>]. The combination has received FDA approval in the United States for patients with MSI-H or dMMR mCRC that has progressed despite other treatments. It is currently not known in which patients with MSI-H mCRC to use combined nivolumab plus ipilimumab, or whether this combination is active in patients who relapse or progress on single-agent checkpoint inhibitor immunotherapy.</p><p></p><p>Approximately 3.5 to 6.5 percent of stage IV CRCs have dMMR [<a href="#rid13">13-15</a>]. The characteristic genetic signature of dMMR tumors is a high number of DNA replication errors (RER+) and MSI-H. Tumors that lack the mismatch repair (MMR) mechanism harbor many more mutations (ie, they are hypermutated) than do tumors of the same type without such MMR defects, and the mutations are also of greater immunogenicity. (See  <a class="medical medical_review" href="/z/d/html/2485.html" rel="external">"Molecular genetics of colorectal cancer", section on 'Mismatch repair genes'</a> and  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Biology of mismatch repair and tumor mutational burden'</a>.)</p><p>Cancers with dMMR appear to be uniquely susceptible to inhibition of immune checkpoints, tolerance mechanisms that suppress the body's immune response to self-antigens in order to minimize autoimmune disease, which may also serve to blunt the immune response to tumor antigens in vivo. One well-characterized checkpoint being targeted in several tumor types, including mCRC, is PD-1. PD-1 is upregulated on activated T cells, and upon recognition of tumor via the T cell receptor, PD-1 engagement by programmed death ligand 1 (PD-L1) results in T cell inactivation  (<a class="graphic graphic_figure graphicRef90346" href="/z/d/graphic/90346.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p>Notably, however, only approximately one-half of dMMR tumors respond to immune checkpoint inhibitor immunotherapy, and other predictive biomarkers are under study for their influence of responsiveness [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H1472405960"><span class="h4">Available data in mCRC</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti PD-1 monotherapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an early phase II study, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, an immunoglobulin G4 (IgG4) monoclonal antagonist antibody to PD-1, was administered intravenously at a dose of 10 mg/kg every 14 days to 11 patients with dMMR mCRC, 21 patients with MMR-proficient (pMMR) mCRC, and 9 patients with noncolorectal dMMR metastatic cancers; all had been heavily pretreated [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent2">In the latest analysis of an expanded cohort of 54 patients with dMMR or pMMR mCRC, presented at the 2016 meeting of the American Society of Clinical Oncology (ASCO; and still unpublished as of March 2022), patients with dMMR mCRC had a 50 percent ORR and a 89 percent disease control rate (DCR; objective response or stable disease) [<a href="#rid18">18,19</a>]. By contrast, the ORR was 0 percent and DCR was 16 percent in the patients with pMMR mCRC. After a median treatment duration of 5.9 months, no patients in the dMMR group who responded had progressed. Overall survival (OS) and PFS were not reached in the dMMR group versus a median PFS of 2.3 months and an OS of 7.6 months in the pMMR group. Interestingly, patients with germline MMR mutations (Lynch syndrome) were less likely to respond than were those with other forms of MMR deficiency (ORR 27 versus 100 percent) [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent2">Largely based upon these data, on May 23, 2017, the FDA granted accelerated approval to <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> for the treatment of patients with advanced MSI-H or dMMR mCRC that has progressed following conventional chemotherapy [<a href="#rid20">20</a>]. The approval of pembrolizumab also extended to a variety of advanced solid tumors other than CRC that were MSI-H or dMMR, that had progressed following prior treatment, and for which there were no satisfactory alternative treatment options, thus representing the first such "tissue-agnostic" anticancer drug approval. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Clinical efficacy of anti-PD-1 therapy'</a>.)</p><p></p><p class="bulletIndent2">High levels of antitumor efficacy for <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> have now been confirmed in other cohorts and in a multicenter phase II trial of patients with previously treated dMMR mCRC [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Benefit for <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, a second anti-PD-1 monoclonal antibody, was shown in a second trial, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02060188%3Fterm%3D02060188%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPN%2FBgNo3ueakSH8vSsT6%2FR6zGyJyOmSgAoj1bgjN4aWgHCilyA8lOaclP8AEfMt3jo%3D&amp;TOPIC_ID=129349" target="_blank">CheckMate 142</a>, in which patients with refractory dMMR (n = 59) or pMMR (n = 23) mCRC received nivolumab (a fully human anti-PD-L1 monoclonal antibody) with or without <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, a monoclonal antibody directed against CTLA-4 [<a href="#rid23">23</a>]. In a preliminary report presented at the 2016 annual ASCO meeting that has not been subsequently published, there were no objective responses among those with pMMR tumors and the median PFS was 1.4 months.</p><p></p><p class="bulletIndent2">In an analysis of the 74 patients with dMMR mCRC treated with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> alone (3 mg/kg every two weeks), at a median follow-up of 12 months, 23 had an objective response (31 percent), and the median duration of response had not been reached. Eight had responses lasting 12 months or longer [<a href="#rid24">24</a>]. Responses were observed regardless of tumor PD-L1 expression level, or<em> BRAF </em>or <em>KRAS </em>mutation status. The most common grade 3 or 4 drug-related adverse events were increased levels of lipase and amylase. In the most recent analysis with long-term follow-up of this cohort, four-year PFS was 36 percent with single-agent nivolumab [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent2">Largely based upon these data, in August 2017, the FDA extended the approval of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> to MSI-H or dMMR mCRC that has progressed following treatment with a fluoropyrimidine, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">Patients who experience disease progression on either of these drugs should not be offered the other. However, an important point is that individuals treated with immune checkpoint inhibitors for dMMR/MSI-H mCRC can have pseudoprogression within the first several months of therapy [<a href="#rid27">27</a>], and response criteria specifically geared toward these drugs (eg, immune-modified response evaluation criteria in solid tumors  (<a class="graphic graphic_table graphicRef116649" href="/z/d/graphic/116649.html" rel="external">table 1</a>)) should be used. (See  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Immunotherapy response criteria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined immunotherapy</strong> – Combined immunotherapy targeting two different immune checkpoints was addressed in cohorts from the CheckMate 142 trial that were treated with combined <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> (four doses of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every three weeks, followed by nivolumab alone 3 mg/kg every two weeks) [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'The "immune synapse"'</a>.)</p><p></p><p class="bulletIndent1">Of the 119 patients in this cohort, 76 percent had received two or more prior systemic therapies. At a median follow-up of 13.4 months, the ORR was 55 percent (51 percent partial, 3 percent complete), and the DCR for 12 weeks or longer was 80 percent. Responses were observed regardless of PD-L1 expression, or <em>BRAF</em> or <em>RAS</em> mutation status. Responses appeared to be durable; at 12 months, 71 percent remained progression free and 85 percent were still alive. Grade 3 or 4 treatment-related adverse events occurred in 32 percent of patients and were manageable. The most common were elevations in aspartate transaminase (AST; 8 percent) or alanine transaminase (ALT; 7 percent). Overall, the most common adverse events of any grade were diarrhea (22 percent, 2 percent severe), fatigue (18 percent, 2 percent severe), pruritus (17 percent, 2 percent severe), and pyrexia (15 percent, none severe).</p><p></p><p class="bulletIndent1">The latest analysis of long-term outcomes from the cohort receiving combined therapy with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> (median follow-up 50.9 months) revealed an objective response rate that had risen to 65 percent, with a 13 percent complete response rate, and median duration of response had still not been reached (range 1.4+ to 58+ months) [<a href="#rid29">29</a>]. Four-year PFS and OS rates were 53 and 71 percent, respectively. Four year PFS with nivolumab alone in this trial was 36 percent [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">These indirect comparisons suggest that combined immunotherapy using <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> and <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> provides improved efficacy over anti-PD-1 monotherapy and has a favorable benefit-risk ratio. Although the final determination of the relative risks and benefits of combined immunotherapy over monotherapy will require large randomized trials (as have been completed in melanoma), the combination of ipilimumab and nivolumab is a reasonable alternative to immune checkpoint inhibitor monotherapy.</p><p></p><p class="bulletIndent1">Largely based on these data, in July 2018, the FDA approved the combination of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> for patients with previously treated MSI-H or dMMR mCRC. It is currently not known in which patients with MSI-H mCRC to use combined nivolumab plus ipilimumab, or whether this combination is active in patients who relapse or progress on single-agent checkpoint inhibitor immunotherapy.</p><p></p><p>An important point is that MSI-H or dMMR may indicate the presence of Lynch syndrome, an inherited condition that predisposes to several cancers, including CRC. Given that Lynch syndrome is more prevalent than previously thought, all patients with an MSI-H/dMMR solid tumor should undergo germline genetic assessment for Lynch syndrome, regardless of family history [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Microsatellite instability testing'</a>.)</p><p class="headingAnchor" id="H721637359"><span class="h3">MMR-proficient tumors with high tumor mutational burden</span><span class="headingEndMark"> — </span>For patients with proficient mismatch repair (pMMR), but high levels of tumor mutational burden (TMB), despite tumor-agnostic FDA approval, a benefit for immune checkpoint inhibitors is not established, and we suggest not pursuing this approach outside of the context of a clinical trial. In our view, use of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> in patients with high TMB should be restricted to those with dMMR or whose tumors harbor selected pathogenic variants in polymerase epsilon (<em>POLE</em>) or polymerase delta1 (<em>POLD1</em>) (collectively referred to as <em>pol-d </em>mutations).</p><p>Approximately 5 percent of pMMR mCRCs have high TMB levels [<a href="#rid31">31,32</a>], although this has been variably quantified. Although such tumors have lower mutational levels than do those with dMMR, TMB appears to be an independent biomarker of benefit for immune checkpoint inhibitor immunotherapy across a variety of tumor types. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumor mutational burden'</a> and  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Frequency of high TMB across tumor types'</a>.)</p><p>A correlation between high TMB and objective response to <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> monotherapy was shown in the phase II KEYNOTE-158 study, which included patients with anal, biliary, cervical, endometrial, salivary, thyroid, or vulvar carcinoma, mesothelioma, a neuroendocrine tumor (NET), or small cell lung cancer [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumors with high mutational burden'</a>.)</p><p>Although none of the patients in this report had mCRC, largely based on this study, in June 2020, the FDA expanded the approval of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> to include adult and pediatric patients with unresectable or metastatic solid tumors, including mCRC, that are tissue TMB-high (≥10 mut/Mb) as defined by the approved companion FoundationOne CDx assay, who have progressed following prior therapy and who have no satisfactory alternative treatment options. However, in a subsequent retrospective analysis of 137 patients treated with pembrolizumab, benefit was limited to patients with high TMB and either dMMR or <em>pol-d</em> pathogenic mutations. Median survival following treatment with pembrolizumab in patients with high TMB without dMMR or <em>pol-d</em> mutations was the same as survival in patients with CRC and low TMB [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumors with high mutational burden'</a>.)</p><p class="headingAnchor" id="H2700647078"><span class="h3">RAS wild-type, BRAF mutated tumors</span><span class="headingEndMark"> — </span>For most patients with <em>RAS</em> wild-type but <em>BRAF</em> V600E mutant mCRC that has progressed after initial chemotherapy, we suggest <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> plus <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a>, rather than cetuximab plus <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>. Based on results from the BEACON trial, for most patients, doublet therapy (ie, encorafenib plus cetuximab) is preferred over a triplet-therapy regimen targeting BRAF, the epidermal growth factor receptor (EGFR), and MEK. This recommendation is consistent with year 2022 guidelines for treatment of mCRC from ASCO [<a href="#rid35">35</a>]. <em>BRAF</em> mutations are associated with resistance to agents that target EGFR, even in the presence of wild-type <em>RAS</em>. (See  <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles", section on 'BRAF mutations'</a>.)</p><p>Resistance to EGFR inhibitors in patients who have mutations in <em>BRAF</em> V600E may be overcome with BRAF inhibitors with or without a MEK inhibitor, in combination with an EGFR inhibitor:</p><p class="bulletIndent1"><span class="glyph">●</span>The combination of a BRAF inhibitor and a MEK inhibitor alone, an approach that has been successfully used for <em>BRAF</em> mutant melanoma, has been only moderately successful for mCRC; in one study, 12 percent of patients achieved a partial response with <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a>, and 56 percent had stable disease as the best response [<a href="#rid36">36</a>]. Others report higher objective response (30 percent) and overall disease control rates (52 percent) with the combination of <a class="drug drug_general" data-topicid="105354" href="/z/d/drug information/105354.html" rel="external">cobimetinib</a> plus <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a> [<a href="#rid37">37</a>]. However, these rates are much lower than those seen in <em>BRAF</em>-mutated melanoma and non-small cell lung carcinoma. (See  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'BRAF mutations'</a> and  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Choice of BRAF plus MEK inhibitor therapy'</a>.)</p><p></p><p class="bulletIndent1">The combination of <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> and <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> has accelerated approval from the FDA for the treatment of adult and pediatric patients one year of age and older with unresectable or metastatic solid tumors harboring mutations in <em>BRAF</em> V600E (including advanced mCRC) who have progressed following prior treatment and have no satisfactory alternative treatment options [<a href="#rid38">38,39</a>]. However, notably, the two trials that were used to support the accelerated approval, the ROAR and NCI MATCH (subprotocol H) trials, specifically excluded patients with mCRC, and thus, benefits are uncertain [<a href="#rid40">40,41</a>]. There are no data to support or refute the efficacy of dabrafenib plus trametinib in a patient who has progressed on <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>. If there are other available chemotherapy regimens or applicable trials, we favor these approaches over second line dabrafenib plus trametinib given the uncertainty of benefit in mCRC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combined inhibition of <em>BRAF</em> and EGFR has also been effective, with responses in 10 to 19 percent in four small trials of <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a> plus <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>, <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> plus panitumumab, and vemurafenib plus cetuximab and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> [<a href="#rid42">42-47</a>].</p><p></p><p class="bulletIndent1">The most influential trial is the phase III BEACON CRC trial, in which patients with <em>RAS</em> wild-type, <em>BRAF</em> V600E mutant mCRC whose disease had progressed after one or two prior regimens were randomly assigned to <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> plus the BRAF inhibitor <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a>, with or without the MEK inhibitor <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">binimetinib</a>, or to <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus cetuximab alone [<a href="#rid45">45</a>]. In the initial report, median OS was significantly higher for the triplet combination compared with both control regimens (9 versus 5.4 months), as was the ORR.</p><p></p><p class="bulletIndent1">However, in a later analysis, while median OS remained significantly higher with triplet therapy compared with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> or irinotecan plus LV and short-term infusional FU (FOLFIRI) plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> (9.3 versus 5.9 months), there was no longer a survival difference between the two targeted regimens [<a href="#rid47">47</a>]. There was still a small (numerical) difference in response rate in favor of the triplet combination (27 versus 20 percent). Both the triplet and the doublet regimens demonstrated improved quality of life compared with standard treatment with an irinotecan/cetuximab combination in an analysis of patient-reported outcomes.</p><p></p><p class="bulletIndent1">Based on these results, consistent with guidelines from the NCCN [<a href="#rid48">48</a>], for most patients, we suggest doublet therapy with <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> over triplet therapy targeting BRAF, EGFR, and MEK for second-line treatment and beyond of <em>BRAF</em> mutated, <em>RAS</em> wild-type mCRC. The combination of encorafenib and cetuximab is now approved by the FDA for the treatment of adults with mCRC with a <em>BRAF </em>V600E mutation, after prior therapy [<a href="#rid49">49,50</a>].</p><p></p><p>Of importance, a significant percentage of <em>BRAF</em> V600E mutant CRC (15 to 25 percent [<a href="#rid15">15,51,52</a>]) have dMMR due to a somatic mutation and these patients are strong candidates for checkpoint inhibitor immunotherapy. The presence of a <em>BRAF</em> V600E mutation strongly suggests that a germline Lynch syndrome mutation is not present. (See <a class="local">'Microsatellite unstable/deficient mismatch repair tumors'</a> above and  <a class="medical medical_review" href="/z/d/html/2605.html" rel="external">"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Clinical manifestations and diagnosis", section on 'Genotype phenotype correlation'</a>.)</p><p class="headingAnchor" id="H2674050161"><span class="h3">RAS wild-type, HER2 overexpressors</span><span class="headingEndMark"> — </span>For patients with <em>RAS</em> wild-type, HER2-overexpressing mCRC who progress on fluoropyrimidine, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, and irinotecan-based chemotherapy, we suggest <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> plus <a class="drug drug_general" data-topicid="127946" href="/z/d/drug information/127946.html" rel="external">tucatinib</a> rather than other trastuzumab-based therapies. Trastuzumab plus tucatinib has a high objective response rate of almost 40 percent (when compared with other HER2-targeted agents evaluated in separate trials), is well-tolerated, and is approved for this population. For patients without access to trastuzumab plus tucatinib, alternative options include trastuzumab plus <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">lapatinib</a> or trastuzumab plus <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a>. Further randomized studies are needed to directly compare trastuzumab plus tucatinib with other HER2 targeted agents.</p><p>We reserve <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> as a later-line option for patients who previously received trastuzumab-based therapy as well as two or more chemotherapy regimens. (See  <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles", section on 'HER2-positive tumors'</a>.)</p><p>Approximately 3 to 5 percent of CRCs have amplification of the <em>HER2</em> oncogene or overexpress its protein product, HER2.The <em>HER2</em> oncogene encodes for a transmembrane glycoprotein receptor that functions as an intracellular tyrosine kinase. As with other EGFR receptors, HER2 is critical in the activation of subcellular signal transduction pathways controlling epithelial cell growth and differentiation, and angiogenesis.</p><p>HER2 overexpression can be detected in tumor tissue by immunohistochemical staining (IHC) for HER2 protein, in situ hybridization for <em>HER2</em> gene amplification, or reverse transcription polymerase chain reaction (RT-PCR) for overexpression of <em>HER2</em> RNA [<a href="#rid53">53,54</a>]. Harmonized recommendations for diagnostic criteria for HER2-amplified mCRC have been proposed [<a href="#rid55">55</a>]. Although circulating tumor DNA (ctDNA) has been used to identify patients for a trial of HER2-directed therapy [<a href="#rid56">56</a>], there is a 10 to 20 percent false-negative rate as compared with tissue analysis [<a href="#rid57">57</a>], and this is not yet a widely accepted approach. Nevertheless, in the absence of tissue, a positive ctDNA result may be used to select patients for HER2-targeted therapy. (See <a class="local">'Multipanel somatic (tumor) and germline genomic testing'</a> above.)</p><p>The following studies have evaluated the benefits of HER2-targeted therapy in <em>RAS</em> wild-type, HER2 positive mCRC:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">Trastuzumab</a><strong> plus </strong><a class="drug drug_general" data-topicid="127946" href="/z/d/drug information/127946.html" rel="external">tucatinib</a> – The combination of trastuzumab plus the selective anti-HER2 tyrosine kinase inhibitor tucatinib was evaluated in an open-label phase II trial (MOUNTAINEER) of 84 patients with HER2-amplified, <em>RAS</em> wild-type mCRC previously treated with fluoropyrimidines, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, and a vascular endothelial growth factor inhibitor [<a href="#rid58">58</a>]. Tucatinib was administered at 300 mg orally twice a day in combination with trastuzumab on day 1 (loading dose of 8 mg/kg for the first cycle, maintenance dose of 6 mg/kg for subsequent cycles) of a 21-day cycle until disease progression or unacceptable toxicity. In a separate treatment arm, 30 patients received single-agent tucatinib arm and were permitted to cross over to combination therapy upon disease progression.</p><p></p><p class="bulletIndent1">At median follow-up of 16 months, the overall response rate for the combination was 38 percent [<a href="#rid58">58</a>]. Median PFS and OS were 8 and 24 months, respectively. The objective response rate with single-agent <a class="drug drug_general" data-topicid="127946" href="/z/d/drug information/127946.html" rel="external">tucatinib</a> was minimal (3 percent), and PFS and OS were not reported because of the high cross-over rate.</p><p></p><p class="bulletIndent1">Grade ≥3 treatment related toxicities for combination therapy included hypertension (7 percent), diarrhea (4 percent), hyperbilirubinemia (6 percent), and increases in AST (6 percent) and ALT (5 percent). Dosing adjustments of <a class="drug drug_general" data-topicid="127946" href="/z/d/drug information/127946.html" rel="external">tucatinib</a> for hepatoxicity and diarrhea are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/128144.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents", section on 'Lapatinib, neratinib, and tucatinib'</a> and  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Lapatinib, pertuzumab, neratinib, and tucatinib'</a>.)</p><p></p><p class="bulletIndent1">Based on these data, the FDA granted accelerated approval for <a class="drug drug_general" data-topicid="127946" href="/z/d/drug information/127946.html" rel="external">tucatinib</a> in combination with <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> in adult patients with<em> RAS </em>wild-type, HER-2 positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trastuzumab</strong><strong> plus </strong><strong>lapatinib</strong> – <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">Trastuzumab</a> plus <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">lapatinib</a> (a tyrosine kinase inhibitor [TKI] against EGFR1 and HER2 that results in inhibition of signaling pathways downstream of HER2) was evaluated in an open-label phase II trial (HERACLES) of 48 patients with <em>KRAS</em> exon 2 wild-type, HER2-overexpressing mCRC [<a href="#rid60">60</a>]. Of these patients, 27 were treated with intravenous trastuzumab (4 mg/kg loading dose initially followed by 2 mg/kg weekly) plus oral lapatinib (1000 mg daily) until disease progression. At a median follow-up of 94 weeks, objective responses were seen in eight patients (30 percent), including one complete response. Treatment was reasonably well tolerated (grade 3 toxicity rate of 22 percent consisting of fatigue, skin rash, or hyperbilirubinemia; no grade 4 or 5 events).</p><p></p><p class="bulletIndent1">In a subsequent analysis, a high rate of central nervous system metastases was noted in 6 of 32 patients (19 percent), mirroring the experience with HER2-targeted therapies in HER2-positive breast cancer [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/775.html" rel="external">"Brain metastases in breast cancer", section on 'Risk factors for central nervous system metastases'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trastuzumab</strong><strong> plus </strong><strong>pertuzumab</strong> – <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">Trastuzumab</a> plus <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a> (a recombinant humanized monoclonal antibody that targets the extracellular HER2 dimerization domain and interferes with downstream HER2 signaling pathways) was evaluated in a phase II basket study (MyPathway) for patients with HER2-overexpressing/amplified tumors other than breast cancer [<a href="#rid62">62,63</a>]. In preliminary results, among the 68 patients with <em>KRAS</em> wild-type and HER2-overexpressing mCRC, objective responses were seen in 21 patients (31 percent) [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">This combination demonstrated lower response rates in a separate phase II basket trial from the Targeted Agent and Profiling Utilization Registry (TAPUR) [<a href="#rid64">64</a>]. Among 28 heavily pretreated patients with HER2-overexpressing mCRC, objective responses were seen in 7 patients (25 percent), all of which were partial responses and no <em>KRAS</em> or <em>BRAF</em> mutations. The disease control rate was 54 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fam-trastuzumab deruxtecan</strong> – <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">Fam-trastuzumab deruxtecan</a> is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. We reserve fam-trastuzumab deruxtecan as a later-line off-label option for patients who have previously received trastuzumab-based therapy as well as two or more prior cytotoxic regimens.</p><p></p><p class="bulletIndent1">For patients with HER2-overexpressing mCRC, we initiate <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> at 5.4 mg/kg intravenously every three weeks, as this dose is equally effective as higher doses and less toxic. In preliminary results of an open-label phase II trial (DESTINY-CRC02), 122 patients with HER-2 overexpressing mCRC were randomly assigned to fam-trastuzumab deruxtecan administered at a dose of either 5.4 mg/kg or 6.4 mg/kg intravenously every three weeks. At median follow-up of ten months, relative to the higher dose (6.4 mg/kg), the lower dose (5.4 mg/kg) demonstrated similar PFS for all patients (median 6 versus 5 months) and objective response rate for those with prior HER2-targeted therapy (41 versus 40 percent). However, the lower dose reduced toxicity (serious adverse event rate 24 versus 31 percent), including rates of drug-related interstitial lung disease (8 versus 13 percent) [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> was demonstrated in an open-label phase II trial (DESTINY-CRC01). In this study, 86 patients with <em>RAS</em> and <em>BRAF </em>V600E wild-type, HER2-overexpressing mCRC who progressed on two or more prior regimens were treated with fam-trastuzumab deruxtecan at 6.4 mg/kg every three weeks [<a href="#rid66">66,67</a>]. Approximately one-third of the patients had received prior HER2-targeted therapies.</p><p></p><p class="bulletIndent1">At median follow-up of 14 months, among the subgroup of 53 patients with tumors that were HER2 3+ IHC or 2+ IHC/positive by in situ hybridization (ISH), the ORR was 45 percent, all of which were partial responses [<a href="#rid67">67</a>]. In this subgroup, ORR was similar regardless of whether patients had received prior HER2-targeted therapy or not (44 versus 46 percent). The median duration of response was 7 months. Median PFS and OS were 7 and 16 months respectively. The response rate was highest among those with 3+ IHC disease (57 percent), whereas there were no objective responses among patients with tumors that were either HER2 2+/negative by ISH or 1+ IHC. However, the grade ≥3 toxicity rate for fam-trastuzumab at the 6.4 mg/kg dose was 65 percent, including decreased neutrophil count (22 percent), anemia (14 percent), and thrombocytopenia (9 percent). The rate of treatment-related interstitial lung disease was 9 percent, including three deaths.</p><p></p><p class="headingAnchor" id="H1257402881"><span class="h3">RAS mutant, HER2 overexpressors</span><span class="headingEndMark"> — </span>There are limited data for the management of patients with mCRC whose tumors are <em>RAS</em> mutated and HER2 overexpression. We refer these patients for clinical trials, where available. In addition, these patients should not receive HER2-targeted therapy outside of a clinical trial, as available data suggest low response rates in this population [<a href="#rid62">62,63</a>]. Preliminary results from a randomized clinical trial (DESTINY-CRC02) suggest clinical activity with <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> in patients with <em>RAS</em>-mutant, HER2 overexpressing mCRC, but further data are necessary prior to its routine use in this group [<a href="#rid65">65</a>]. (See <a class="local">'RAS-mutated tumors'</a> below.)</p><p class="headingAnchor" id="H387769743"><span class="h3">RAS-mutated tumors</span><span class="headingEndMark"> — </span>For most patients with <em>RAS</em>-mutated mCRC who progress on fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and VEGF inhibitor therapy and do not have a second actionable genetic alteration, we encourage enrollment in clinical trials, where available (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=129349" target="_blank">www.clinicaltrials.gov</a>).</p><p>For such patients with <em>KRAS </em>G12C mutant mCRC who decline or do not have access to clinical trials, we suggest either <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a> plus <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> or <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> rather than single-agent treatment or other systemic agents. Either of these combinations are appropriate as they have not been directly compared in randomized trials. For patients who are unable to tolerate the combination due to toxicity from the EGFR inhibitor, single-agent sotarasib or adagrasib is a reasonable alternative.</p><p>Patients with <em>RAS</em>-mutated mCRC do not benefit from EGFR inhibitors. In particular, patients with mCRC that harbors a <em>KRAS</em> G12C mutation have poor treatment outcomes [<a href="#rid68">68,69</a>]. Treatment-related resistance rapidly develops in these tumors, and studies suggest that the primary resistance mechanism is increased EGFR signaling [<a href="#rid70">70,71</a>]. Further details on mechanisms of disease resistance in <em>RAS</em>-mutated colorectal cancer are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2485.html" rel="external">"Molecular genetics of colorectal cancer", section on 'RAS'</a> and  <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles", section on 'RAS'</a>.)</p><p>Divarasib, <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a>, and <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> are irreversible inhibitors that target KRAS G12C. In patients with <em>KRAS</em> G12C mutant mCRC, these drugs have been evaluated in combination with EGFR inhibitors (to reverse tumor resistance to these inhibitors) and as monotherapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sotorasib</strong><strong> plus </strong><strong>panitumumab</strong> – In patients with treatment-refractory <em>KRAS</em> G12C mutant mCRC, the combination of <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a> plus <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> improved PFS and was well-tolerated in a randomized phase III trial (CodeBreaK 300) [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1">In early phase clinical trials, <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a> was initially evaluated as a single-agent (CodeBreaK100) [<a href="#rid73">73,74</a>] and in combination with <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> (CodeBreaK 101) [<a href="#rid75">75</a>]. These data led to the evaluation of sotorasib plus panitumumab in an open-label phase III trial (CodeBreaK 300) [<a href="#rid72">72</a>]. In this study, 160 patients with mCRC and <em>KRAS</em> G12C mutation who progressed on or were intolerant of fluoropyrimidine, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> were randomly assigned to panitumumab in combination with sotorasib either at a dose of 960 mg daily (53 patients) or 240 mg daily (53 patients), or investigator's choice of <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> or <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> (54 patients).</p><p></p><p class="bulletIndent1">At median follow-up of eight months, <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a> plus <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> improved PFS over <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> or <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> for both sotarasib doses (median PFS 5.6 versus 2.2 months, hazard ratio [HR] 0.49, 95% CI 0.3-0.8 for sotorasib 960 mg plus panitumumab; median PFS 3.9 versus 2.2 months, HR 0.58, 95% CI 0.36-0.93 for sotorasib 240 mg plus panitumumab). Objective responses were highest for sotorasib at 960 mg plus panitumumab (26 percent) compared with sotorasib at 240 mg plus panitumumab (6 percent) and trifluridine-tipiracil or regorafenib (0 percent). OS results are immature.</p><p></p><p class="bulletIndent1">Grade ≥3 toxicity rates were lower for <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> plus <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a> at 960 mg (36 percent) or 240 mg (30 percent) versus trifluridine-tipiricil or <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> (43 percent). The most frequent grade ≥3 toxicities for panitumumab plus either sotorasib at 960 mg or 240 mg included diarrhea (4 and 6 percent), nausea (2 and 4 percent), hypomagnesemia (6 and 8 percent), rash (6 and 2 percent), dermatitis acneiform (11 and 4 percent), and skin-related toxic effect (4 and 2 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adagrasib</strong><strong> plus </strong><strong>cetuximab</strong> – <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">Adagrasib</a> plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> is another option for treatment-refractory <em>RAS</em> mutant mCRC with high objective response rates and durable disease control.</p><p></p><p class="bulletIndent1">In a nonrandomized multicohort phase I/II trial (KRYSTAL-1), 76 patients with previously treated mCRC harbori<em>ng a KRAS</em> G12C mutation were treated with either <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> alone or in combination with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At median follow-up of 18 months, among the 32 patients treated with <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, the ORR for adagrasib plus cetuximab was 46 percent and the disease control rate was 100 percent. The median duration of response was 7.6 months, and median PFS was 6.9 months.</p><p></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At median follow-up of 20 months, among the 44 patients who received <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> monotherapy, the objective response rate (ORR) was 23 percent and the disease control rate was 86 percent. The median duration of response was 4.3 months, and median PFS was 5.6 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Divarasib</strong> – The use of divarasib remains investigational in mCRC. Divarasib was evaluated in a phase I trial of 137 patients with advanced or metastatic treatment-refractory solid tumors with a <em>KRAS</em> G12C mutation [<a href="#rid77">77</a>]. Among the subgroup of 55 patients with mCRC, the confirmed response rate was 29 percent, and median PFS was 6 months. Divarasib was also well tolerated among patients with mCRC (grade ≥3 toxicity rate of 7 percent).</p><p></p><p class="headingAnchor" id="H3950264360"><span class="h3">RET fusion-positive tumors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">Selpercatinib</a> is an option for refractory mCRC with a rearranged during transfection (<em>RET</em>) gene fusion and disease progression on or following prior systemic treatment. Efficacy in 45 patients with a variety of solid tumors containing a <em>RET</em> fusion gene was addressed on the Libretto-001 basket trial [<a href="#rid78">78</a>]. In the entire cohort, the objective response rate was 44 percent and median duration of response was 24.5 months; two of the ten patients with advanced colon cancer had a partial response (20 percent) and the median duration of response was 9.4 months. The most common grade ≥3 treatment-emergent adverse effects were hypertension and transaminase elevation.</p><p>In September 2022, the FDA granted a tissue-agnostic, accelerated approval of <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> for adult patients with locally advanced or metastatic solid tumors with a <em>RET</em> gene fusion and disease progression on or following prior systemic treatment who have no satisfactory alternative treatment options. Unfortunately, only 0.2 to 1.2 percent of advanced CRCs harbor a <em>RET</em> fusion [<a href="#rid79">79-81</a>].</p><p class="headingAnchor" id="H3154863881"><span class="h3">TRK fusion-positive tumors</span><span class="headingEndMark"> — </span>For patients who have tropomyosin receptor kinase (TRK) fusion-positive mCRC, we suggest a TRK inhibitor (<a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>) rather than another form of therapy for treatment at progression after the initial regimen.</p><p>Genomic translocations in one of several neurotrophic tyrosine kinase receptor (<em>NTRK</em>) genes that lead to the constitutive activation of a TRK are found in approximately 0.5 to 1 percent of mCRCs, and they appear to identify a subset of patients with poor prognosis. (See  <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Prevalence'</a>.)</p><p>More importantly, finding one of these fusion genes/oncoproteins in the tumor identifies a subset of patients who might benefit from a TRK inhibitor. (See  <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Treatment with TRK inhibitors'</a>.)</p><p>Two such drugs, <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> and <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>, are approved in the United States for use in adults and children with TRK fusion-positive solid tumors for which there are no other effective treatments. Larotrectinib is also approved by the European Medicines Agency (EMA). Entrectinib has also been approved in Japan for treatment of 10 tumor types with a <em>NTRK</em> gene fusion, including CRC.</p><p>Although sequencing trials are not available in mCRC or any other cancer type, it is reasonable to consider a TRK inhibitor early in the course of chemotherapy treatment (such as after progression on the initial line of chemotherapy) in patients with fusion-positive advanced cancers, given the very high response rates and durable disease control. This subject, as well as a general discussion of side effects from TRK inhibitors, is presented in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Timing of therapy for patients with advanced disease'</a> and  <a class="medical medical_review" href="/z/d/html/122713.html" rel="external">"TRK fusion-positive cancers and TRK inhibitor therapy", section on 'Side effects'</a>.)</p><p class="headingAnchor" id="H46270221"><span class="h2">Not eligible for or progressing during targeted therapy</span></p><p class="headingAnchor" id="H1796870755"><span class="h3">The cytotoxic chemotherapy backbone</span><span class="headingEndMark"> — </span>For fit patients who were initially treated with an oxaliplatin-containing chemotherapy doublet (ie, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> [LV] and short-term infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> [FU; FOLFOX] or oxaliplatin plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> [CAPOX/XELOX]), we switch to FOLFIRI or <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> alone at the time of disease progression. For patients initially treated with FOLFIRI, we switch to an oxaliplatin-based regimen at the time of progression.</p><p>The optimal sequence of <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> and irinotecan-containing chemotherapy for mCRC remains unresolved, and may differ between patients based on tumor-related heterogeneity and pharmacogenetic issues. As noted above, exposure to all active agents is probably more important than the specific sequence of administration [<a href="#rid10">10,82</a>]. Nevertheless, most American oncologists initiate chemotherapy for mCRC with FOLFOX or CAPOX/XELOX, using <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> alone [<a href="#rid83">83</a>] or irinotecan-based regimens such as FOLFIRI as second-line therapy after the failure of FOLFOX.</p><p>The available data suggest similar survival outcomes and efficacy regardless of the specific order of administration:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irinotecan</strong><strong> after </strong><strong>oxaliplatin</strong><strong> failure</strong> – Although limited, the most mature data from three series suggest response rates between 4 and 20 percent, and PFS of 2.5 to 7.1 months, respectively, for patients receiving a FOLFIRI-like regimen after progression on FOLFOX [<a href="#rid84">84-86</a>].</p><p></p><p class="bulletIndent1">Single-agent <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> is also an option. Available data suggest small differences in efficacy between second-line FOLFIRI and irinotecan. In the small phase II DaVINCI trial [<a href="#rid87">87</a>] performed in Australia and New Zealand, response rates were similar for single-agent irinotecan (350 mg/m<sup>2</sup> every 21 days) and FOLFIRI (11 percent in both arms), with small but not statistically significant improvements in PFS (6.2 versus 4 months) and OS (15.4 versus 11.2 months) favoring FOLFIRI, while overall quality of life favored irinotecan. In the meta-analysis accompanying the DaVINCI trial, there were no significant differences in response rate, PFS, or OS between single-agent irinotecan and FOLFIRI. However, severe diarrhea and alopecia were more common with single-agent irinotecan at 350 mg/m<sup>2</sup>. Given what appears to be similar outcomes in second-line following oxaliplatin-5FU combinations, patients should be informed of the differences in toxicity and infusion requirements of these regimens. Notably, the starting dose of single agent irinotecan for older patients and those with performance status ≥2 is 300 mg/m<sup>2</sup>, though clinicians could consider starting with lower doses, and dose escalation as tolerated given the risk of neutropenia and severe enteritis.</p><p></p><p class="bulletIndent1">S-1 is an oral fluoropyrimidine that includes ftorafur (tegafur), gimeracil (5-chloro-2,4 dihydropyridine, a potent inhibitor of dihydropyrimidine dehydrogenase [DPD]), and oteracil (potassium oxonate, which inhibits phosphorylation of intestinal FU, thought responsible for treatment-related diarrhea). It is available in some countries outside of the United States. Where S-1 is available, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus S-1 represents a reasonable alternative to FOLFIRI for second-line treatment after failure of first-line FOLFOX [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1">The contribution of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> to the efficacy of second-line irinotecan-based chemotherapy is discussed below. (See <a class="local">'Antiangiogenesis therapy'</a> below and <a class="local">'RAS/BRAF wild-type tumors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxaliplatin</strong><strong> after </strong><strong>irinotecan</strong><strong> failure</strong> – The benefit of oxaliplatin-based therapy in patients failing an initial irinotecan-based regimen has been addressed in four multicenter trials:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an early crossover phase III trial, both sequences of FOLFOX followed by FOLFIRI, or FOLFIRI followed by FOLFOX were directly compared, and both sequences achieved a prolonged survival and similar efficacy, although the toxicity profiles differed (grade 3 or 4 mucositis, nausea/vomiting, and grade 2 alopecia were more frequent with FOLFIRI, but grade 3 or 4 neutropenia and neurosensory toxicity were more frequent with FOLFOX) [<a href="#rid84">84</a>]. The response rate with FOLFOX6 in patients failing initial FOLFIRI was 15 percent, and the PFS was 4.2 months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The largest trial, conducted in the United States and Canada, randomly allocated 812 irinotecan-refractory patients to one of three different treatment groups [<a href="#rid89">89,90</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">Oxaliplatin</a> alone (85 mg/m<sup>2</sup> every two weeks)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The de Gramont FU/LV regimen (LV 200 mg/m<sup>2</sup> over two hours, followed by FU [bolus 400 mg/m<sup>2</sup> and a 22-hour infusion of 600 mg/m<sup>2</sup> per day], days 1 and 2 every two weeks)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The combination (FOLFOX4)  (<a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">table 2</a>)</p><p></p><p class="bulletIndent2">The ORR with FOLFOX4 was significantly higher than with either <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> alone or FU/LV (10 versus 1 percent with the other regimens, respectively) [<a href="#rid90">90</a>]. Median time to progress (TTP) was also significantly longer with FOLFOX4 as compared with FU/LV (4.2 versus 2.1 months), and more patients had symptomatic benefit (28 versus 15 percent). The higher frequency of grade 3 or 4 toxicity with FOLFOX4 (ie, diarrhea, nausea, vomiting, neutropenia) did not translate into a higher rate of treatment discontinuation or mortality [<a href="#rid89">89,90</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Second-line FOLFOX4 was directly compared with CAPOX (<a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> 130 mg/m<sup>2</sup> over 30 minutes on day 1 every three weeks plus <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> 1000 mg/m<sup>2</sup> orally twice daily on days 1 to 14) in a phase III trial of 627 patients failing initial FU/<a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> [<a href="#rid91">91</a>]. Results with XELOX were not inferior to FOLFOX4 in terms of response rates, TTP, or median OS (12.5 and 11.9 months for FOLFOX and XELOX). Toxicity profiles were also comparable, with the exception of fewer grade 3 or 4 neutropenia (5 versus 35 percent), and more grade 3 or 4 diarrhea (19 versus 5 percent) and hand-foot syndrome (4 versus &lt;1 percent) with XELOX.</p><p></p><p>In the United States, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> is approved in combination with infusional FU/LV for patients who recur or progress during or within six months of completion of first-line irinotecan-based therapy. <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">Capecitabine</a>/oxaliplatin could be considered in patients who desire to avoid a central venous line ambulatory infusion pump, although increasingly oxaliplatin is being administered through a central line because of pain with peripheral vein administration. The contribution of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> to the efficacy of oxaliplatin/fluoropyrimidine regimens is discussed below.</p><p class="headingAnchor" id="H1134529842"><span class="h4">Patients initially treated with FOLFOXIRI</span><span class="headingEndMark"> — </span>The best chemotherapy backbone regimen for individuals who are treated initially with a three drug regimen (eg, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> plus <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, LV plus short-term FU [FOLFOXIRI],  (<a class="graphic graphic_table graphicRef70559" href="/z/d/graphic/70559.html" rel="external">table 3</a>)) is not established. For patients who are <em>RAS</em> and <em>BRAF</em> wild-type and have not received an EGFR inhibitor, and who discontinued FOLFOXIRI for reasons other than disease progression, options include an EGFR inhibitor, FOLFIRI, FOLFOX, or reintroduction of FOLFOXIRI [<a href="#rid92">92</a>]. If an antiangiogenic agent was not used first-line, then <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> plus either FOLFOX or FOLFIRI are additional options.</p><p>For patients who are <em>RAS/BRAF</em> wild-type and who discontinued FOLFIRINOX because of disease progression, options include an EGFR inhibitor (either <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>) alone or with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>.</p><p>For patients previously treated with FOLFIRINOX who have received an anti-VEGF agent, and (if <em>RAS</em> and <em>BRAF</em> wild-type) an EGFR inhibitor, and who require additional therapy, options include single-agent <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> with or without <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>, or <a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">fruquintinib</a>. (See <a class="local">'Subsequent therapy'</a> below.)</p><p class="headingAnchor" id="H1955292748"><span class="h4">Patients not eligible for intensive therapy</span><span class="headingEndMark"> — </span>The best way to treat patients with a borderline performance status or extensive comorbidity who initially received fluoropyrimidine monotherapy is not clear, and several options may be considered.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Capecitabine</strong><strong> plus </strong><strong>bevacizumab</strong> – ORRs with second-line <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> monotherapy are quite low in patients with FU-refractory disease [<a href="#rid93">93,94</a>]. As such, capecitabine alone is an inappropriate treatment strategy for patients with progressive mCRC on initial intravenous FU-based regimens. However, capecitabine plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> might be an option, if it was not used for initial therapy, and there are no contraindications to the use of bevacizumab. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Not candidates for intensive therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irinotecan</strong><strong> monotherapy</strong> – Another option is <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> monotherapy. As a single agent, irinotecan has demonstrated clinical benefit after FU failure in patients with mCRC [<a href="#rid95">95-98</a>]. As an example, in a trial of 279 patients with FU-refractory disease who were randomly assigned to best supportive care with or without irinotecan, the irinotecan group had superior one-year survival (36 versus 14 percent) and quality of life [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1">Different administration schedules for <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> (weekly, every two weeks, or every three weeks) appear to result in similar therapeutic outcomes, although in one report, the every-three-week schedule was associated with significantly less grade 3 diarrhea (36 versus 19 percent) than a weekly regimen [<a href="#rid99">99</a>]. Diarrhea is the dose-limiting side effect of irinotecan and may be severe; early use of <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> decreases its severity and is essential to prevent treatment-related mortality. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Raltitrexed</strong> – <a class="drug drug_general" data-topicid="10087" href="/z/d/drug information/10087.html" rel="external">Raltitrexed</a> (Tomudex), a folate analog, is a pure thymidylate synthase inhibitor [<a href="#rid100">100</a>]. It is not more active than FU and is not approved in the United States [<a href="#rid101">101-103</a>]. In at least one randomized trial that assigned 905 patients with mCRC to raltitrexed, infusional FU, or bolus plus short-term infusional FU/LV (the de Gramont regimen), raltitrexed was associated with the greatest toxicity and worst health-related quality of life [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1">However, <a class="drug drug_general" data-topicid="10087" href="/z/d/drug information/10087.html" rel="external">raltitrexed</a>, which is not available in the United States, may be a useful substitute for FU in patients with DPD deficiency (which markedly increases FU toxicity) or possibly as a component of second-line therapy in patients failing <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> or <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> [<a href="#rid104">104-107</a>]. (See  <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"</a>.)</p><p></p><p class="headingAnchor" id="H2746833978"><span class="h3">Antiangiogenesis therapy</span></p><p class="headingAnchor" id="H1709369965"><span class="h4">Patients initially treated with bevacizumab</span><span class="headingEndMark"> — </span>For patients treated with a first-line bevacizumab-containing chemotherapy regimen, we suggest continuation of an antiangiogenic agent at the time of progression. For most patients, we suggest <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> rather than <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> beyond progression in conjunction with a second-line fluoropyrimidine-based chemotherapy backbone, particularly if an EGFR inhibitor is not indicated (eg, those with a <em>RAS</em> or <em>BRAF</em> mutation), as long as drug therapy is well tolerated. However, if bevacizumab is used as a component of the second-line chemotherapy regimen for patients with <em>RAS</em> wild-type disease, it should not be administered concurrently with an EGFR-targeting monoclonal antibody (MoAb). (See <a class="local">'Dual antibody therapy'</a> below.)</p><p class="headingAnchor" id="H1690649395"><span class="h5">Continuation of bevacizumab</span><span class="headingEndMark"> — </span>In view of the increasing use of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in first-line regimens, an important clinical issue is whether it should be continued in patients who switch to an alternative regimen after cancer progression on first-line bevacizumab-containing therapy. An association between survival and exposure to bevacizumab beyond first progression was suggested in an analysis of the observational BRiTE registry of 1953 patients who progressed after receiving a first-line bevacizumab-containing regimen [<a href="#rid108">108</a>], in a preliminary report from the ARIES observational cohort study [<a href="#rid109">109</a>], and from a retrospective analysis of 573 patients treated with and without second-line bevacizumab from community-based United States Oncology practices [<a href="#rid110">110</a>].</p><p>This issue was directly studied in two trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In the European TML (ML18147) study, 820 patients with unresectable mCRC progressing within three months of receiving first-line chemotherapy with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> were randomly assigned to fluoropyrimidine-based chemotherapy with or without bevacizumab (2.5 mg/kg/week) [<a href="#rid111">111</a>]. Continuation of bevacizumab with the second-line chemotherapy regimen was associated with a significant improvement in PFS (median 5.7 versus 4.1 months) and OS (median 11.2 versus 9.8 months), and bevacizumab-related adverse events were not increased compared with historical data of first-line bevacizumab treatment. Although significantly more patients achieved disease control in the bevacizumab group (68 versus 54 percent), ORRs in both arms were low (5.4 versus 3.9 percent for bevacizumab and no bevacizumab, respectively). Based upon these results, in January 2013, the FDA approved bevacizumab for use in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for treatment of patients with mCRC whose disease had progressed on a first-line bevacizumab-containing regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benefit was also suggested in a second trial, the BEBYP trial, which randomly assigned 185 patients undergoing first-line fluoropyrimidine-plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> chemotherapy to second-line FOLFOX or FOLFIRI with or without bevacizumab [<a href="#rid112">112</a>]. Accrual to the trial was prematurely stopped when the results of the TML trial became known. Median PFS was significantly improved by continuation of bevacizumab with the second-line regimen (median 6.8 versus 5 months), although the differences in ORRs to the second-line regimen (17 versus 21 percent), and DCRs overall (58 versus 70 percent) were not statistically significant.</p><p></p><p>A different question, whether to switch to <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or continue with second-line <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in patients with <em>RAS</em> wild-type tumors progressing on first-line bevacizumab, was addressed in the phase II PRODIGE 18 trial [<a href="#rid113">113</a>]. Continuation with bevacizumab was associated with a numerically higher, but not statistically significant, median PFS (7.1 versus 5.6 months) and OS (15.8 versus 10.4 months) compared with cetuximab plus chemotherapy. These results favor continuation of bevacizumab with an alternative chemotherapy backbone in patients who progress with first-line bevacizumab plus chemotherapy.</p><p class="headingAnchor" id="H3393294520"><span class="h5">Role of aflibercept</span><span class="headingEndMark"> — </span>Intravenous <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> (VEGF Trap, Zaltrap) is a recombinant fusion protein, consisting of vascular endothelial growth factor (VEGF) binding portions from key domains of human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G1. It acts as a soluble "decoy" receptor that binds to human VEGF-A, VEGF-B, and placental growth factor (PIGF), thereby inhibiting the binding of these ligands and activation of their respective receptors. In cell-free systems, this molecule binds with higher affinity to VEGF-A than does <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> [<a href="#rid114">114</a>].</p><p><a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">Aflibercept</a> is approved in the United States for use in combination with FOLFIRI for the treatment of patients with mCRC that is resistant to or has progressed following an oxaliplatin-containing regimen. Approval was based on the placebo-controlled VELOUR trial, in which 1226 patients with oxaliplatin-refractory mCRC were randomly assigned to aflibercept (4 mg/kg intravenously) or placebo, plus FOLFIRI, every two weeks until progression [<a href="#rid115">115</a>]. Median OS was significantly longer in patients treated with aflibercept (13.5 versus 12.1 months) as was median PFS (6.9 versus 4.7 months). Benefit and safety were similar regardless of prior <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> exposure [<a href="#rid116">116</a>].</p><p>While the side effect profile of <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> plus FOLFIRI in the VELOUR trial was consistent with other agents targeting VEGF (bleeding, hypertension, proteinuria, wound infection, arterial thromboembolic events), rates of diarrhea, mucositis, complicated neutropenia, infection, and fatigue associated with aflibercept in this trial were higher than usually seen with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, as were rates of treatment discontinuation for toxicity or refusal (30 versus 12 percent). (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p>There are no randomized trials directly comparing second-line <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> in patients who progressed on first-line bevacizumab. Data are available from a multicenter retrospective analysis of 681 patients treated with second-line aflibercept (n = 326) or bevacizumab (n = 355) after progressing on first-line bevacizumab; 81 percent had <em>RAS</em>-mutated tumors [<a href="#rid117">117</a>], and it was concluded that after adjusting for age, performance status, PFS of first-line therapy, primary tumor location, metastasis location, and <em>RAS</em>/<em>BRAF</em> status, the use of bevacizumab was associated with longer PFS and OS (HR 0.71, 95% CI 0.59-0.86), as well as better tolerability.</p><p>As with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, because of the risk of impaired wound healing, at least 28 days (and preferably six to eight weeks) should elapse between major surgery and administration of <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>, except in emergency situations. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Delayed wound healing'</a>.)</p><p class="headingAnchor" id="H3692318614"><span class="h4">Ramucirumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">Ramucirumab</a> is a recombinant MoAb of the IgG1 class that binds to the VEGFR-2, blocking receptor activation. The efficacy of ramucirumab for second-line treatment of mCRC was addressed in the double blind phase III RAISE trial in which 1072 patients with progressing after first-line therapy with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, and a fluoropyrimidine were randomly assigned to FOLFIRI with ramucirumab (8 mg/kg intravenously every two weeks) or placebo until disease progression, unacceptable toxicity, or death [<a href="#rid118">118</a>]. Median survival was modestly but significantly greater with ramucirumab (13.3 versus 11.7 months), as was median PFS (5.7 versus 4.5 months). ORRs were comparable in the two arms. Grade 3 or worse side effects that were more prominent with ramucirumab included neutropenia (38 versus 23 percent), hypertension (11 versus 3 percent), and fatigue (12 versus 8 percent).</p><p>Based on these results, <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">ramucirumab</a> was approved in April 2015 for use in combination with FOLFIRI for the treatment of mCRC in patients whose disease has progressed on a first-line bevacizumab-, oxaliplatin-, and fluoropyrimidine-containing regimen. However, given this modest degree of benefit, the expense of this agent [<a href="#rid119">119</a>], and the competing data indicating benefit from continuation of second-line <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in this same setting, we do not consider ramucirumab the agent of choice if continued VEGF inhibition beyond first-line progression is considered.</p><p class="headingAnchor" id="H2730639279"><span class="h3">RAS/BRAF wild-type tumors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a> and <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>, therapeutic MoAbs that target the EGFR, both have well-documented and comparable single-agent activity in patients with previously treated mCRC that lacks mutations in <em>RAS</em> and <em>BRAF </em>V600E [<a href="#rid120">120-122</a>]. Regimens that combine an EGFR inhibitor with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> alone or a chemotherapy doublet are also efficacious, with the exception of regimens that contain <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> with a non-infusional fluoropyrimidine (ie, CAPOX/XELOX). (See  <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">"Systemic therapy for metastatic colorectal cancer: General principles", section on 'Predictive biomarkers'</a>.)</p><p class="headingAnchor" id="H3722373104"><span class="h4">No prior initial therapy with cetuximab/panitumumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a> (or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>) is useful in combination with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> for patients with <em>RAS</em> and <em>BRAF</em> wild-type tumors that are refractory to irinotecan and as a single agent for those who are intolerant of irinotecan-based chemotherapy. If rapid tumor growth is observed after first-line FOLFOX plus bevacizumab-based therapy, the addition of cetuximab (or panitumumab) to irinotecan-based therapy is a reasonable option to elicit higher anti-tumor activity, particularly because the biology of the disease in these patients might not allow for a step-wise, sequential therapeutic approach. By contrast, in a case of a rather indolent, slowly progressive tumor, sequential use of agents (irinotecan first, followed by irinotecan plus cetuximab [or panitumumab]) might be preferable.</p><p>Another alternative is to continue <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> with the second-line cytotoxic chemotherapy backbone. Emerging data support the view that EGFR inhibitors do not appear to be useful for right-sided tumors in the setting of first-line therapy. However, whether these results can be extrapolated to later lines of therapy is not clear; there are few data addressing this issue [<a href="#rid123">123</a>] and no consensus. The authors and editors associated with this topic review would not withhold EGFR inhibitors for second-line treatment for right sided <em>RAS/BRAF</em> wild-type tumors. However, other clinicians would favor the use of continued bevacizumab over an EGFR inhibitor for right-sided tumors after failure of an initial bevacizumab-containing regimen. (See <a class="local">'Initial therapy with bevacizumab'</a> below and <a class="local">'Patients initially treated with bevacizumab'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of monotherapy</strong></p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a>, a mouse/human chimeric MoAb, binds to the EGFR of both tumor and normal cells, competitively inhibiting ligand binding, and inducing receptor dimerization and internalization. It is unclear whether these actions represent the mechanism of antitumor action. Cetuximab is useful in combination with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> for patients with wild-type <em>RAS</em> tumors who are refractory to irinotecan and as a single agent for those who are intolerant of irinotecan-based chemotherapy. The approved dosing regimen is weekly, although at least some data support the safety and efficacy of every-other-week dosing. (See <a class="local">'Are cetuximab and panitumumab interchangeable?'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a> monotherapy was compared with best supportive care (BSC) in a randomized trial of 572 patients who had failed or were intolerant of all recommended therapies [<a href="#rid120">120</a>]. Median OS was significantly better with cetuximab (6.1 versus 4.6 months), as were measures of health-related quality of life, including physical function and global health scores. In a subsequent reanalysis, the benefits of cetuximab were restricted to patients whose tumors lacked a <em>KRAS</em> mutation [<a href="#rid124">124,125</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">Panitumumab</a> is a fully human MoAb specific for the extracellular domain of EGFR. The benefit of panitumumab monotherapy was initially shown in a multicenter trial in which 463 patients refractory to FU, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, and <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> were randomly assigned to BSC with or without panitumumab (6 mg/kg every two weeks) [<a href="#rid121">121</a>]. The ORR with panitumumab was 10 percent, and 27 percent had stable disease; the corresponding rates with BSC alone were 0 and 10 percent. Patients receiving panitumumab were significantly more likely to be alive and progression free at eight weeks (49 versus 30 percent). The lack of a survival difference was likely due to panitumumab use after crossover in the BSC group [<a href="#rid126">126</a>]. In a later reanalysis, efficacy was limited to patients whose tumors were wild type for <em>KRAS </em>exon 2 (partial response and stable disease in 17 and 34 percent, respectively, versus 0 and 12 percent with mutated <em>KRAS</em>) [<a href="#rid127">127</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined therapy</strong> – Combined therapy with a cytotoxic chemotherapy backbone increases ORRs and TTP compared with monotherapy, but treatment-related toxicity is worse.</p><p></p><p class="bulletIndent1">Two randomized trials have explored the activity of <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> in combination with second-line FOLFIRI after failure of initial FOLFOX; neither included <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> as a component of the first-line regimen in all patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the large EPIC (Erbitux Plus <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">Irinotecan</a> in Colorectal cancer) trial, in which 1300 patients with EGFR-expressing, but not <em>RAS</em>-selected, mCRC who had failed initial FOLFOX therapy were randomly assigned to single-agent irinotecan with or without <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, the addition of cetuximab quadrupled the response rate (16 versus 4 percent), significantly prolonged PFS (4 versus 2.6 months), and despite the higher frequency of side effects, was associated with better quality of life [<a href="#rid128">128</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similarly, the BOND trial compared <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> (350 mg/m<sup>2</sup> every three weeks, 180 mg/m<sup>2</sup> every two weeks, or 125 mg/m<sup>2</sup> weekly for four of every six weeks) plus weekly <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> versus cetuximab alone in 329 patients with irinotecan-refractory mCRC [<a href="#rid129">129</a>]. Combined therapy was associated with a significantly better response rate (23 versus 11 percent) and TTP (4.1 versus 1.5 months) but only a trend towards better median survival (8.6 versus 6.9 months).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized trial of <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> plus FOLFIRI versus FOLFIRI alone after failure of initial FU-containing chemotherapy (two-thirds prior <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, 20 percent prior <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>) also showed that, in the <em>KRAS</em> wild-type group (n = 597), the addition of panitumumab was associated with a significant improvement in response rate (35 versus 10 percent) and median PFS (5.9 versus 3.9 months) [<a href="#rid130">130</a>] but no statistically significant difference in OS.</p><p></p><p>These results confirm that the addition of <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> to an irinotecan-based chemotherapy regimen after failure of initial FU-containing chemotherapy is associated with greater treatment activity than is monotherapy. Although the combination of panitumumab and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> is not approved by the FDA for the treatment of <em>RAS</em> and <em>BRAF</em> wild-type mCRC, we offer this combination in this population since it is safe and effective. This approach is consistent with consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) and the ESMO [<a href="#rid48">48,131</a>]. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Benefit of cetuximab and panitumumab'</a>.)</p><p class="headingAnchor" id="H88365604"><span class="h5">Initial therapy with bevacizumab</span><span class="headingEndMark"> — </span>A separate question, given the demonstrated benefit of second-line <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in patients progressing on an initial bevacizumab-containing regimen, is whether it is preferable to continue second-line bevacizumab or switch to a regimen containing an EGFR inhibitor. (See <a class="local">'Patients initially treated with bevacizumab'</a> above.)</p><p>The benefit of adding <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> to the cytotoxic chemotherapy backbone in <em>RAS</em> wild-type tumors that have progressed after first-line bevacizumab was directly addressed in the PRODIGE 18 trial [<a href="#rid113">113</a>]. Continuation with bevacizumab was associated with a numerically higher but not statistically significant median PFS and OS advantage compared with cetuximab plus chemotherapy. In our view, there is insufficient evidence to draw any conclusions from these data, and either bevacizumab or an EGFR inhibitor is acceptable in this setting, although use of an EGFR inhibitor for right sided tumors in the second-line setting is controversial. (See <a class="local">'No prior initial therapy with cetuximab/panitumumab'</a> above and  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'EGFR inhibitors versus bevacizumab and the influence of tumor sidedness'</a>.)</p><p class="headingAnchor" id="H1895310200"><span class="h5">Are cetuximab and panitumumab interchangeable?</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">Cetuximab</a> and <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> appear to have comparable efficacy when used for single agents for salvage therapy in patients with chemotherapy-refractory mCRC [<a href="#rid120">120,121,132-134</a>], and when used for first-line or second-line therapy of mCRC in conjunction with an irinotecan-based chemotherapy regimen.</p><p>Both MoAbs target the same antigen (EGFR), and preclinical data suggest a similar mode of action (interference with ligand binding, downregulation of signaling activity, internalization of receptors) [<a href="#rid135">135</a>]. From a pharmacologic standpoint, the main difference between both agents lies in their IgG backbones: <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> is a chimeric mouse/human MoAb, while <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> is a completely human MoAb. As a result, the incidence of hypersensitivity reactions with panitumumab is lower, and this eliminates the need for routine premedication before therapy. (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Cetuximab'</a>.)</p><p>The difference in the original on-label dosing schedules (every two weeks for <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>, weekly for <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>) were based more on how the respective trials leading to approval by the FDA were designed than on true pharmacokinetic, pharmacodynamic, or pharmacogenomic differences. The two drugs have similar half-lives (approximately seven days) and pharmacokinetics [<a href="#rid136">136</a>], and results from a nonrandomized phase II trial [<a href="#rid137">137</a>] and a multicenter retrospective analysis [<a href="#rid138">138</a>] suggest that cetuximab at a dose of 500 mg/m<sup>2</sup> every two weeks results in similar plasma concentrations and single-agent activity as does weekly dosing. In April, the United States Prescribing Information for cetuximab was modified to allow for every two week dosing as an alternative to weekly dosing, for cetuximab when used as monotherapy, or in combination with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>  (<a class="graphic graphic_table graphicRef62096" href="/z/d/graphic/62096.html" rel="external">table 4</a>), or in combination with irinotecan plus LV and short-term FU (FOLFIRI,  (<a class="graphic graphic_table graphicRef62726" href="/z/d/graphic/62726.html" rel="external">table 5</a>)) [<a href="#rid139">139</a>].</p><p>In clinical practice, there is no therapeutic preference for using <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> versus <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> either as monotherapy, or in combination with chemotherapy. However, the lower rate of infusion reactions with panitumumab favors the use of this agent in regions with a high rate of cetuximab-related infusion reactions (eg, middle southeastern region of the United States, including North Carolina, Arkansas, Missouri, Virginia, and Tennessee). We consider that the addition of panitumumab to an <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> or oxaliplatin-containing chemotherapy regimen in patients with <em>RAS</em> and <em>BRAF</em> wild-type tumors is appropriate, an approach that is also allowed in consensus-based guidelines from the NCCN and ESMO [<a href="#rid48">48,131</a>]. (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Cetuximab'</a> and  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Benefit of cetuximab and panitumumab'</a>.)</p><p>Patients receiving either drug should undergo periodic monitoring of serum electrolytes, including magnesium and potassium. (See  <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'Anti-EGFR monoclonal antibodies'</a>.)</p><p class="headingAnchor" id="H766352929"><span class="h4">Prior initial therapy with cetuximab or panitumumab</span><span class="headingEndMark"> — </span>For patients with <em>RAS</em> and <em>BRAF</em> wild-type mCRC who progress on initial treatment with chemotherapy plus an EGFR inhibitor (ie, <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>) and have no other actionable molecular alterations, our approach to second-line therapy is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who previously received FOLFOX plus an EGFR inhibitor, we suggest FOLFIRI plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus bevacizumab rather than other systemic agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who previously received FOLFIRI plus an EGFR inhibitor, we suggest FOLFOX plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or CAPOX plus bevacizumab rather than other systemic agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those who are not candidates for <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, chemotherapy alone is an acceptable alternative. Contraindications to bevacizumab are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Contraindications'</a>.)</p><p></p><p>This approach to second-line therapy exposes the tumor to agents not previously received. It is also extrapolated from the initial management of mCRC, where the addition of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> to chemotherapy confers an OS advantage and is a treatment option for patients with either right- or left-sided primary tumors. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Efficacy and toxicity of bevacizumab and biosimilars'</a> and  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'EGFR inhibitors versus bevacizumab and the influence of tumor sidedness'</a>.)</p><p>In contrast, randomized trials have established PFS but not OS benefit for EGFR inhibitor re-challenge in second-line therapy for RAS wild-type mCRC [<a href="#rid140">140</a>]. Re-challenging with regimens that include an EGFR inhibitor may be reserved for third or later lines of therapy. (See <a class="local">'Re-challenge with previously used classes of agents'</a> below.)</p><p>Studies have evaluated EGFR inhibitor challenge in <em>RAS</em> wild-type metastatic CRC. The rationale for this approach is that resistant <em>RAS</em> and <em>EGFR</em> ectoderm clones, which can develop during initial treatment with these agents [<a href="#rid141">141</a>], decay over time once the EGFR inhibitor is discontinued for approximately four months or longer [<a href="#rid142">142</a>]. This results in reemergence of tumor sensitivity to EGFR blockade [<a href="#rid143">143,144</a>].</p><p>Re-challenge with <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> was evaluated in a randomized phase II trial of 153 patients with mCRC initially treated with FOLFIRI plus cetuximab. At median follow-up of 35 months, the combination of FOLFOX plus cetuximab failed to improve PFS over FOLFOX alone in the entire study population [<a href="#rid140">140</a>]. Among the subset of patients with <em>RAS, BRAF, and PIK3CA</em> wild-type disease, the addition of cetuximab to FOLFOX improved PFS (median 6.9 versus 5.3 months, HR 0.56, 95% CI 0.33-0.94), but not OS (median 24 versus 20 months, HR 0.57, 95% CI 0.32-1.02).</p><p>Clinical trials are evaluating the use of circulating tumor DNA (ctDNA) to identify patients who benefit from EGFR inhibitor re-challenge [<a href="#rid145">145-150</a>], but this approach remains investigational.</p><p class="headingAnchor" id="H3475237490"><span class="h2">Treatments not used</span></p><p class="headingAnchor" id="H1711375550"><span class="h3">What is the role of panitumumab after progression on cetuximab?</span><span class="headingEndMark"> — </span>A separate questions is whether resistance to <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> also predicts resistance to <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>. The majority of patients who have been evaluated in a trial setting do not achieve durable benefit from the use of panitumumab in patients who progress on cetuximab, and vice versa. In our view, this approach should only be undertaken in the context of a clinical trial aimed at better defining this question. This approach is consistent with consensus-based guidelines from the NCCN and ESMO [<a href="#rid48">48,131</a>].</p><p>Whether <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> is active in patients whose cancer has progressed on <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> therapy (and vice versa) is unclear. The similar mode of action would seem to support the existence of cross resistance, but there are few data that inform this issue. Two clinical trials of panitumumab in patients progressing on a cetuximab-containing regimen have come to different conclusions:</p><p class="bulletIndent1"><span class="glyph">●</span>In the first, 26 patients with <em>KRAS</em> wild-type mCRC received <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> after progressing on <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> plus <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> [<a href="#rid151">151</a>]. A partial response was achieved in three (12 percent), and seven additional patients (27 percent) had stable disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, in a second trial of 20 patients with <em>KRAS</em> wild-type mCRC who had progressed on <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, no patient responded, although 45 percent had stable disease (no progression for at least two cycles) [<a href="#rid152">152</a>]. The authors concluded that <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> was of minimal benefit in cetuximab-refractory disease.</p><p></p><p>A possible explanation for these discrepant results has been provided by studies examining the mutational landscape of cetuximab-refractory tumors:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, investigators used a cetuximab-sensitive human CRC cell line to develop a resistant version by prolonged in vitro exposure to <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> [<a href="#rid153">153</a>]. The cetuximab-resistant cells contained a secondary EGFR mutation in the extracellular domain of the receptor that impaired binding of cetuximab but not other EGFR ligands, including <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>. This specific mutation was identified in 2 of 10 tumors from people with cetuximab resistance, one of whom received panitumumab and had an objective response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report of tissue samples derived from 37 patients with CRC who became refractory to <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>, a complex pattern of mutations was observed, converging on two main patterns of resistance: activating mutations affecting EGFR downstream signaling and mutations in the EGFR ectodomain that disrupt antibody receptor binding, a subset of which prevented binding to cetuximab but not <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> [<a href="#rid154">154</a>].</p><p></p><p>Thus, while there may be a small subset of patients with cetuximab-refractory <em>RAS</em> wild-type tumors who will respond to <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>, the best way to identify this subset is unclear. Further details are discussed separately. (See <a class="local">'Prior initial therapy with cetuximab or panitumumab'</a> above.)</p><p class="headingAnchor" id="H2807878842"><span class="h3">Dual antibody therapy</span><span class="headingEndMark"> — </span>Based upon the available data, a chemotherapy regimen containing both <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and an anti-EGFR MoAb cannot be considered a standard approach for treatment of <em>RAS/BRAF</em> wild-type mCRC for second-line therapy or beyond outside of a clinical trial.</p><p>The results of the phase II BOND-2 trial, which compared a combination of <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a>/<a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> with (CBI) or without (CB) <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> as last-line therapy in patients with chemorefractory mCRC generated interest in dual-antibody combinations [<a href="#rid155">155</a>]. BOND-2 reported unprecedented outcome results for patients previously treated with FU, irinotecan, and (in 85 to 90 percent of cases) <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> with regard to response rate (20 versus 37 for CB and CBI, respectively), TTP (4.9 versus 7.3 months), and OS (11.4 versus 14.5 months). The toxicity profile was also tolerable.</p><p>However:</p><p class="bulletIndent1"><span class="glyph">●</span>BOND-2 was a small randomized phase II trial of 83 patients treated in a few highly specialized cancer centers, thus limiting the extrapolation of the findings to the unselected patient population treated by community oncologists. The unexpectedly long median OS in both treatment arms underscores the highly select nature of the patient population enrolled to the study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who were considered candidates for the trial had already received (and apparently tolerated) several lines of therapy and still maintained a good enough performance status (0 to 1)  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 6</a>) to be enrolled in the trial. This again underscores the fact that the patients enrolled on BOND-2 were highly selected and clearly not representative of the typical patient population with refractory mCRC.</p><p></p><p class="bulletIndent1">This issue might in part explain the unexpected results of both the PACCE and the CAIRO2 trials, both of which suggested a possible detrimental impact of concurrent use dual antibodies targeting VEGF and the EGFR in the setting of first-line therapy. (See  <a class="medical medical_review" href="/z/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Dual antibody therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients on BOND-2 were all bevacizumab-naive so that the data cannot necessarily be used to justify therapy with dual antibodies in patients who have already received <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> as part of their prior palliative medical therapy. This approach was being studied for second-line therapy in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fresults%2FNCT00499369%3Fterm%3DSWOG%2B0600%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPyfAbUrGw6u9ZNcIqaduCvWUMRCUFUz%2BUzGs%2B%2FyHNhdsvBx8dfmYQ%2FkJ2n8%2BXzPOeTugIFGjNtV68jKolwSwCi&amp;TOPIC_ID=129349" target="_blank">SWOG S0600</a>; however, the protocol was terminated prematurely due to insufficient accrual.</p><p></p><p>The benefit of combining <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> and <a class="drug drug_general" data-topicid="94963" href="/z/d/drug information/94963.html" rel="external">ramucirumab</a> was addressed in the E7208 trial, in which 102 patients with <em>RAS</em> wild-type mCRC progressing after a fluoropyrimidine-, oxaliplatin-, and bevacizumab-containing regimen were randomly assigned to <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus cetuximab with ramucirumab (ICR) or without ramucirumab (IC) [<a href="#rid156">156</a>]. The ICR regimen was modified after the initial 35 patients were enrolled because of excessive toxicity. In a preliminary report presented at the 2018 annual American Society of Clinical Oncology (ASCO) meeting, patients assigned to ICR had similar median PFS (5.8 versus 5.7 months), and combination treatment was also more toxic (myelosuppression, hypertension, mucositis). Subset analysis suggested that patients who progressed while not receiving <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> and those with a longer time since last treatment might have preferentially benefited from dual therapy, but this is hypothesis generating at most.</p><p class="headingAnchor" id="H552729592"><span class="h1">SUBSEQUENT THERAPY</span><span class="headingEndMark"> — </span>For patients who have been exposed to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) agent, and (if <em>RAS</em> and <em>BRAF</em> wild-type) an epidermal growth factor receptor (EGFR) inhibitor, options include <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> with or without <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>, or <a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">fruquintinib</a>.</p><p class="headingAnchor" id="H3487499558"><span class="h2">Trifluridine-tipiracil with or without bevacizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">Trifluridine-tipiracil</a> plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> is an option for patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, and an EGFR inhibitor (if <em>RAS </em>wild-type). Trifluridine-tipiracil monotherapy may be offered to patients who are unable to tolerate or have contraindications to bevacizumab.</p><p><a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">Trifluridine-tipiracil</a> (TAS-102) is an oral cytotoxic agent that consists the nucleoside analog <a class="drug drug_general" data-topicid="10021" href="/z/d/drug information/10021.html" rel="external">trifluridine</a> (trifluorothymidine, a cytotoxic antimetabolite that, after modification within tumor cells, is incorporated into DNA causing strand breaks) and tipiracil, a potent thymidine phosphorylase inhibitor, which inhibits trifluridine metabolism and has antiangiogenic properties as well [<a href="#rid157">157</a>].</p><p><a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">Trifluridine-tipiracil</a> is administered twice daily on days 1 to 5 and 8 to 12 of a 28-day cycle, and <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> is administered at 5 mg/kg on days 1 and 15 of a 28-day cycle. Other studies suggest that an every-two-weeks schedule of administration of trifluridine-tipiracil (twice daily on days 1 to 5 of a 14-day cycle) with bevacizumab (5 mg/kg on day 1 of a 14-day cycle) is associated with less toxicity, especially neutropenia [<a href="#rid158">158</a>] This schedule is a reasonable alternative for patients who have difficulty tolerating the standard dosing of this combination.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trifluridine-tipiracil</strong><strong> plus </strong><strong>bevacizumab</strong> – Based on initial data from a phase II trial [<a href="#rid159">159</a>], an open-label phase III trial (SUNLIGHT) was conducted to evaluate the addition of <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> to <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> in 492 patients with mCRC who progressed on one to two lines of systemic therapy [<a href="#rid160">160</a>]. Most patients had received prior therapy with bevacizumab (72 percent) and had <em>RAS</em>-mutated tumors (70 percent). Patients were randomly assigned to either trifluridine-tipiracil plus bevacizumab or trifluridine-tipiracil alone. At median follow-up of 14 months, the addition of trifluridine-tipiracil to bevacizumab improved OS (median OS 11 versus 8 months, one-year OS 43 versus 30 percent, HR 0.61, 95% CI 0.49-0.77) and PFS (median PFS 6 versus 2 months, one-year PFS HR 0.44, 95% CI 0.36-0.54) [<a href="#rid160">160</a>]. OS and PFS benefit were seen across all prespecified subgroups, including patients previously treated with bevacizumab. Objective response rates were also higher with the combination (6 versus 1 percent). Grade ≥3 toxicity rates were similar between the treatment arms (72 versus 70 percent). The combination had higher rates of grade 3 to 4 hypertension (6 versus 1 percent) and neutropenia (43 versus 32 percent), but not febrile neutropenia (one patient for the combination versus six patients for trifluridine-tipiracil monotherapy).</p><p></p><p class="bulletIndent1">Based on these data, the US Food and Drug Administration (FDA) approved <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> in combination with <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> for the treatment of adult patients with mCRC previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if <em>RAS</em> wild-type, an anti-EGFR therapy [<a href="#rid161">161</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trifluridine-tipiracil</strong><strong> monotherapy</strong> – An OS benefit of <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> as a single-agent in refractory mCRC was initially suggested in a randomized placebo-controlled phase II trial of 172 Japanese patients with refractory mCRC [<a href="#rid162">162</a>].</p><p></p><p class="bulletIndent1">This clinical benefit was subsequently confirmed in two subsequent placebo-controlled phase III trials (the RECOURSE and TERRA trials) [<a href="#rid163">163,164</a>]. In the RECOURSE trial, 800 patients with mCRC refractory to or intolerant of fluoropyrimidines, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, and EGFR inhibitors (if <em>KRAS</em> wild-type) were randomly assigned to <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> or placebo [<a href="#rid163">163</a>]. When compared with placebo, trifluridine-tipiracil improved OS (median 7 versus 5 months, HR 0.68, 95% CI 0.58-0.81), irrespective of prior <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> use. In a separate analysis, among patients with a <em>KRAS</em> G12C mutated tumors, trifluridine-tipiracil did not improve OS over placebo; these data suggest less clinical benefit for this agent in this population [<a href="#rid165">165</a>]. Although trifluridine-tipiracil also improved the disease control rate (44 versus 16 percent), only eight patients had an objective response (versus one patient in the placebo arm).</p><p></p><p class="bulletIndent1">The most frequently observed toxicities were gastrointestinal and hematologic. The rate of serious adverse events were similar for <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> versus placebo (30 versus 34 percent), and there was one treatment-related death with trifluridine-tipiracil. Importantly, gastrointestinal toxicities with trifluridine-tipiracil were almost all grade 1 and 2 with few grade ≥3 events recorded. That is a relevant quality-of-life benefit for patients with longstanding treatment-refractory disease who often experience gastrointestinal distress from their disease.</p><p></p><p class="bulletIndent1">Largely based upon these results, the FDA approved <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> as a single agent for the treatment of adult patients with mCRC previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if <em>RAS</em> wild-type, an anti-EGFR therapy [<a href="#rid161">161</a>]. Trifluridine-tipiracil is also approved in Japan for treatment of refractory mCRC.</p><p></p><p class="headingAnchor" id="H3905851211"><span class="h2">Regorafenib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">Regorafenib</a> is an option for patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, anti-EGFR inhibitor (if <em>RAS </em>wild-type), and molecularly targeted therapy, if appropriate. Regorafenib may also be offered to those who progress on <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> with or without <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>.</p><p>We suggest initiating <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> with 80 mg per day rather than 160 mg (the approved dose), escalating the dose weekly in the absence of toxicity, and ending at 160 mg daily for 21 days of each 28-day cycle.</p><p><a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">Regorafenib</a> is an orally active inhibitor of angiogenic (including the VEGF receptors [VEGFRs] 1 to 3), stromal, and oncogenic receptor tyrosine kinases. It is structurally similar to <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> and targets a variety of kinases implicated in angiogenic and tumor growth-promoting pathways.</p><p>Activity in refractory mCRC was initially shown in the CORRECT trial, in which 760 patients who had progressed after multiple standard therapies were randomly assigned to best supportive care plus <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> (160 mg orally once daily for three of every four weeks) or placebo [<a href="#rid166">166</a>]. Patients assigned to regorafenib had a modest though statistically significant improvement in median overall survival (OS; 6.4 versus 5 months, hazard ratio [HR] 0.77, 95% CI 0.64-0.94), and the difference in progression-free survival (PFS), while very small, was statistically significant (HR 0.49, median 1.9 versus 1.7 months). While the disease control rate (DCR) was higher with regorafenib (41 versus 15 percent), only five patients (1 percent) experienced a partial response. The group receiving regorafenib had more grade 3 or 4 hand-foot skin reaction (17 versus 0.4 percent), fatigue (10 versus 5 percent), hypertension (7 versus 1 percent), diarrhea (7 versus 1 percent), and skin rash (6 versus 0 percent). Fatal hepatic failure occurred in 1.6 percent of patients treated with regorafenib versus 0.4 percent in the placebo group. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p>Largely based on this study, in 2012, <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> received approval from the FDA for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, and, if <em>KRAS</em> wild-type, an EGFR inhibitor. It was approved by the European Medicines Agency (EMA) in 2013.</p><p>Benefit for <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> monotherapy was confirmed in the multicenter CONCUR trial, in which 204 Asian patients with mCRC who progressed after standard therapies were randomly assigned to regorafenib (160 mg daily for 21 of every 28 days) or placebo [<a href="#rid167">167</a>]. Regorafenib was associated with a significantly longer median PFS (3.2 versus 1.7 months) and OS (8.8 versus 6.3 months). As was seen in the CORRECT trial, the DCR was significantly higher with regorafenib (51 versus 7 percent), although only six patients (4 percent) achieved a partial response (versus none in the placebo group).</p><p>The initial approved dose of <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a> (160 mg daily for 21 days of every 28-day cycle) may be too high for many patients. In the phase II ReDOS trial, a weekly dose escalating strategy (starting with 80 mg daily, escalating weekly in the absence of treatment-related toxicity to a target of 160 mg daily) allowed more patients to initiate the third cycle of therapy compared with starting at 160 mg per day (43 versus 26 percent) [<a href="#rid168">168</a>]. Median OS also trended better in the dose escalation cohort (9.8 versus 6 months), and toxicity was more favorable.</p><p class="headingAnchor" id="H1061988501"><span class="h2">Fruquintinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">Fruquintinib</a> is an option for patients with mCRC previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; a VEGF inhibitor such as <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>; and an EGFR inhibitor (for <em>RAS </em>wild-type tumors). Fruquintinib may also be offered to those who progress on <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> with or without bevacizumab. In phase III trials of treatment-refractory mCRC, fruquintinib, a selective small molecule inhibitor of VEGFR 1, 2, and 3 tyrosine kinases, improved OS and PFS over placebo [<a href="#rid169">169,170</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In an international, double-blind, placebo controlled phase III trial (FRESCO-2), 691 patients with heavily pretreated mCRC were randomly assigned 2:1 to receive either <a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">fruquintinib</a> (5 mg orally once daily on days 1 through 21 of a 28-day cycle) or placebo until disease progression or intolerable toxicity [<a href="#rid170">170</a>]. Patients had previously received chemotherapy (fluoropyrimidine, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, or <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>); a VEGF inhibitor; targeted agents for tumors with actionable molecular alterations (an EGFR inhibitor if <em>RAS</em> wild-type; immunotherapy if mismatch repair deficient [dMMR] or microsatellite instability-high (MSI-H); or a BRAF inhibitor if <em>BRAF</em> V600E-mutant); and had progressed on or were intolerant of <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a>, <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>, or both.</p><p></p><p class="bulletIndent1">At median follow-up of 11 months, relative to placebo, <a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">fruquintinib</a> improved PFS (median 3.7 versus 1.8 months, HR 0.32, 95% 0.27-0.39), OS (median 7.4 versus 4.8 months, HR 0.66, 95% CI 0.55-0.80), and the disease control rate (56 versus 16 percent). Fruquintinib also conferred an OS benefit across clinically relevant subgroups including<em> RAS</em> status, prior VEGF or EGFR inhibitors, prior <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> and/or <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>, and the presence or absence of liver metastases. The grade ≥3 toxicity rate was higher for fruquintinib than placebo (63 versus 50 percent). Common grade ≥3 toxicities for fruquintinib included hypertension (14 percent), asthenia (8 percent), and hand-foot syndrome (6 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar OS benefits were seen for <a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">fruquintinib</a> in a separate randomized, double-blind, placebo-controlled phase III trial conducted in China (FRESCO) [<a href="#rid169">169</a>]. In this study, 416 patients with treatment-refractory mCRC were randomly assigned to either fruquintinib or placebo until disease progression or intolerable toxicity. Patients had disease progression after two or more lines of therapy that did not include a VEGFR inhibitor (such as <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>), but could include a VEGF inhibitor (such as <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a>). At median follow-up of 13 months, fruquintinib improved OS (median 9.3 versus 6.6 months, HR 0.65, 95% CI 0.51-0.83), and PFS (median 3.7 versus 1.8 months, HR 0.26, 95% CI 0.21-0.34). Grade ≥3 toxicity was higher for fruquintinib compared with placebo (61 versus 19 percent).</p><p></p><p><a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">Fruquintinib</a> is approved by the FDA for adult patients with mCRC previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, a VEGF inhibitor, and, if <em>RAS</em> wild-type and medically appropriate, an EGFR inhibitor [<a href="#rid171">171</a>]. Fruquintinib is also approved in China by the National Medical Products Administration (NMPA) for patients with mCRC who have progressed on at least two prior systemic therapies include fluoropyrimidine, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, and <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, with or without prior use of VEGF or EGFR inhibitors [<a href="#rid172">172,173</a>].</p><p class="headingAnchor" id="H506946367"><span class="h2">Re-challenge with previously used classes of agents</span><span class="headingEndMark"> — </span>For patients with mCRC who progress on all available systemic agents, we offer enrollment in clinical trials, where available. Patients must have adequate performance status and a tumor-directed therapeutic approach must still warranted and desired, after a realistic discussion with the patient and/or family about the risks and benefits.</p><p>For patients who are ineligible for or do not have access to clinical trials, one option is re-challenging with a regimen initially used in the treatment sequence, especially if the regimen was discontinued because of toxicity and not disease progression [<a href="#rid174">174</a>]. During the lengthy phase of sequential therapy, tumors may retain or regain sensitivity to previously used drugs. (See <a class="local">'Subsequent treatment and the continuum of care model'</a> above.)</p><p>Examples of systemic agents that could be reused include:</p><p class="bulletIndent1"><span class="glyph">●</span>FOLFOX or CAPOX. Of note, caution is warranted during <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> re-challenge. The risk of oxaliplatin infusion reaction is higher in patients with prior exposure, and tend to occur earlier (eg, cycles 2 to 3) in the treatment course [<a href="#rid175">175,176</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <em>RAS</em> wild-type disease, regimens that include an EGFR inhibitor such as <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>. (See <a class="local">'Prior initial therapy with cetuximab or panitumumab'</a> above.)</p><p></p><p>In a randomized phase II trial (VELO), re-challenge with <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>, an EGFR inhibitor, was investigated as third-line therapy in 62 patients with <em>RAS </em>wild-type tumors. All patients were initially treated with chemotherapy plus an EGFR inhibitor and did not receive an EGFR inhibitor for at least four months during second-line therapy [<a href="#rid145">145</a>]. The addition of panitumumab to <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> improved PFS (median 4 versus 2.5 months, HR 0.48, 95% CI 0.28-0.82) but not OS (13 versus 12 months, HR 0.96, 95% CI 0.54-1.71) [<a href="#rid177">177</a>]. (See <a class="local">'Trifluridine-tipiracil with or without bevacizumab'</a> above.)</p><p class="headingAnchor" id="H944196586"><span class="h1">LOCAL THERAPIES FOR METASTATIC DISEASE</span><span class="headingEndMark"> — </span>Some patients may have metastatic disease limited to (or predominantly progressing within) one organ system, such as the liver, lungs, ovaries, or adrenal glands. For such patients, alternatives to systemic therapy include local treatment strategies, such as limited surgical resection, stereotactic body radiation therapy (SBRT), or ablative therapies. Further details are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2495.html" rel="external">"Locoregional methods for management and palliation in patients who present with stage IV colorectal cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2796.html" rel="external">"Surgical resection of pulmonary metastases: Outcomes by histology", section on 'Colorectal cancer'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115954.html" rel="external">"Hepatic resection for colorectal cancer liver metastasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2515.html" rel="external">"Nonsurgical local treatment strategies for colorectal cancer liver metastases"</a>.)</p><p></p><p class="headingAnchor" id="H455988024"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115274.html" rel="external">"Society guideline links: Colorectal cancer"</a>.)</p><p class="headingAnchor" id="H2025511323"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15412.html" rel="external">"Patient education: Colon and rectal cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/874.html" rel="external">"Patient education: Colon and rectal cancer (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/860.html" rel="external">"Patient education: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2452193814"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Molecular testing</strong> – The approach to later lines of systemic therapy in mCRC is based on molecular testing and prior therapy. Regimens listed for patients with no molecular marker can be used for subsequent therapy in those with an identified molecular marker. (See <a class="local">'Multipanel somatic (tumor) and germline genomic testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selecting therapy</strong> – At disease progression, select patients may be candidates for retreatment with the original regimen (eg, those on maintenance chemotherapy) or a switch to a different regimen (eg, those with disease progression on or intolerance to therapy). (See <a class="local">'Subsequent treatment and the continuum of care model'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>dMMR/MSI-H</strong> <strong>tumors</strong> – For patients whose tumors have high levels of microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) not previously exposed to an immune checkpoint inhibitor, we suggest immune checkpoint inhibitor immunotherapy rather than other systemic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Options include <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 7</a>), <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 8</a>), or the combination of nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>. (See <a class="local">'Microsatellite unstable/deficient mismatch repair tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>TRK</em></strong><strong> fusions</strong> – For patients who have tropomyosin receptor kinase (TRK) fusion-positive mCRC progressing after initial therapy, we suggest a TRK inhibitor (<a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>) rather than other therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'TRK fusion-positive tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RAS wild-type,</strong> <strong>HER2-overexpressing tumors</strong> – For patients with <em>RAS</em> wild-type, HER2-overexpressing mCRC who progress on fluoropyrimidine-, oxaliplatin-, or irinotecan-based chemotherapy, we suggest <a class="drug drug_general" data-topicid="10101" href="/z/d/drug information/10101.html" rel="external">trastuzumab</a> plus <a class="drug drug_general" data-topicid="127946" href="/z/d/drug information/127946.html" rel="external">tucatinib</a> rather than other trastuzumab-based therapies (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients without access to trastuzumab plus tucatinib, alternative options include trastuzumab plus <a class="drug drug_general" data-topicid="10093" href="/z/d/drug information/10093.html" rel="external">lapatinib</a> or trastuzumab plus <a class="drug drug_general" data-topicid="85639" href="/z/d/drug information/85639.html" rel="external">pertuzumab</a>. (See <a class="local">'RAS wild-type, HER2 overexpressors'</a> above.)</p><p></p><p class="bulletIndent1">We reserve <a class="drug drug_general" data-topicid="126410" href="/z/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> as a later-line option for patients who previously received trastuzumab-based therapy as well as two or more chemotherapy regimens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>RAS</em></strong><strong> wild-type, </strong><strong><em>BRAF</em></strong><strong>-mutated tumors</strong> – For most patients with <em>RAS</em> wild-type but <em>BRAF</em> V600E mutant mCRC, we suggest <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> plus <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a>, rather than cetuximab plus <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>) or a triplet regimen targeting BRAF, the epidermal growth factor receptor (EGFR), and MEK (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'RAS wild-type, BRAF mutated tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>RAS</em></strong><strong>-mutated tumors, without another actionable target</strong> – For patients with <em>RAS-</em>mutated mCRC who progress on fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and VEGF inhibitor therapy and who do not have a second actionable genetic alteration, we encourage enrollment in clinical trials, where available.</p><p></p><p class="bulletIndent1">For such patients with <em>KRAS</em> G12C mutant mCRC who decline or do not have access to clinical trials, we suggest either <a class="drug drug_general" data-topicid="131755" href="/z/d/drug information/131755.html" rel="external">sotorasib</a> plus <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> or <a class="drug drug_general" data-topicid="140357" href="/z/d/drug information/140357.html" rel="external">adagrasib</a> plus <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> rather than single-agent treatment or other systemic agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients who are unable to tolerate the combination due to toxicity from the EGFR inhibitor, single-agent sotarasib or adagrasib is a reasonable alternative. (See <a class="local">'RAS-mutated tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No molecular marker (</strong><strong><em>RAS</em></strong><strong>/</strong><strong><em>BRAF</em></strong><strong> wild-type) or progression on targeted therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior doublet </strong><strong>oxaliplatin</strong><strong>-based chemotherapy</strong> – For fit patients initially treated with an oxaliplatin-containing chemotherapy doublet (ie, FOLFOX or CAPOX/XELOX), we switch to FOLFIRI  (<a class="graphic graphic_table graphicRef76300" href="/z/d/graphic/76300.html" rel="external">table 9</a>) or <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> alone at the time of disease progression. For patients initially treated with FOLFIRI, we switch to an oxaliplatin-based regimen. (See <a class="local">'The cytotoxic chemotherapy backbone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior FOLFOXIRI</strong> – For patients previously treated with FOLFOXIRI, choice depends on the reason for discontinuation and prior exposure to EGFR inhibitors and antiangiogenic agents.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who discontinued FOLFOXIRI because of disease progression, options include an EGFR inhibitor (either <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>) alone  (<a class="graphic graphic_table graphicRef76312 graphicRef86309" href="/z/d/graphic/76312.html" rel="external">table 10A-B</a>) or in combination with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>  (<a class="graphic graphic_table graphicRef62096" href="/z/d/graphic/62096.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who discontinued FOLFOXIRI for reasons other than disease progression and have not received an EGFR inhibitor, options include an EGFR inhibitor plus <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, FOLFIRI, or FOLFOX, or reintroduction of FOLFOXIRI  (<a class="graphic graphic_table graphicRef70559" href="/z/d/graphic/70559.html" rel="external">table 3</a>). If an antiangiogenic agent was not used first-line, then <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> plus either FOLFOX  (<a class="graphic graphic_table graphicRef62939" href="/z/d/graphic/62939.html" rel="external">table 11</a>) or FOLFIRI  (<a class="graphic graphic_table graphicRef64505" href="/z/d/graphic/64505.html" rel="external">table 12</a>) or FOLFOXIRI  (<a class="graphic graphic_table graphicRef127023" href="/z/d/graphic/127023.html" rel="external">table 13</a>) are additional options.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Addition of antiangiogenic or EGFR inhibitor</strong> – Second-line fluoropyrimidine-based chemotherapy may be combined with antiangiogenic agents or EGFR inhibitors, but not both. (See <a class="local">'Dual antibody therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior </strong><a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> – For patients initially treated with bevacizumab plus cytotoxic chemotherapy, we suggest the continuation of an antiangiogenic agent in conjunction with a second-line fluoropyrimidine-based chemotherapy regimen, as tolerated (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For most patients we suggest bevacizumab rather than <a class="drug drug_general" data-topicid="17100" href="/z/d/drug information/17100.html" rel="external">aflibercept</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients initially treated with bevacizumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No prior </strong><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a><strong> or </strong><a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> – Cetuximab or panitumumab may be used for second-line therapy if neither was administered first-line, although use of these agents for second-line therapy of right sided tumors is controversial. (See <a class="local">'No prior initial therapy with cetuximab/panitumumab'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If rapid tumor growth was observed following <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> plus FOLFOX, the combination of <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> (or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>) plus irinotecan-based therapy is a reasonable alternative to monotherapy with either agent, as the disease tempo might not allow for a stepwise, sequential approach. For an indolent, slowly progressive tumor, sequential use of agents (<a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> first, followed by irinotecan plus cetuximab [or panitumumab]) might be preferable.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior </strong><a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a><strong> or </strong><a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a> – For patients with <em>RAS</em> and <em>BRAF</em> wild-type mCRC who progress on initial therapy with chemotherapy plus an EGFR inhibitor (ie, cetuximab or panitumumab) and have no other actionable molecular alterations, our approach to second-line therapy is as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For those who previously received FOLFOX plus an EGFR inhibitor, we suggest FOLFIRI plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> plus bevacizumab rather than other systemic agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Prior initial therapy with cetuximab or panitumumab'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For those who previously received FOLFIRI plus an EGFR inhibitor, we suggest FOLFOX plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> or CAPOX plus bevacizumab rather than other systemic agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For those who are not candidates for <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, chemotherapy alone is an acceptable alternative.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients unable to tolerate intensive therapy</strong> – For patients not able to tolerate intensive therapy, treatment with sequential single chemotherapy agents, single targeted agents, or the combination of <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">capecitabine</a> plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> are all reasonable approaches. Supportive care alone is also an option. (See <a class="local">'Patients not eligible for intensive therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent therapy</strong> – For patients who have been exposed to fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, and (if <em>RAS</em> and <em>BRAF</em> wild-type) an EGFR inhibitor, options include <a class="drug drug_general" data-topicid="104185" href="/z/d/drug information/104185.html" rel="external">trifluridine-tipiracil</a> with or without <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="86690" href="/z/d/drug information/86690.html" rel="external">regorafenib</a>, or <a class="drug drug_general" data-topicid="143377" href="/z/d/drug information/143377.html" rel="external">fruquintinib</a>. (See <a class="local">'Subsequent therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Re-challenge with previously used classes of agents</strong> – For patients with mCRC who progress on all available systemic agents, we offer enrollment in clinical trials, where available. For patients who are ineligible for or do not have access to clinical trials, one option is re-challenging with a regimen initially used in the treatment sequence. Options include FOLFOX, CAPOX, or regimens that include an EGFR inhibitor (<a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">panitumumab</a>) for those with<em> RAS</em> wild-type disease. (See <a class="local">'Re-challenge with previously used classes of agents'</a> above.)</p><p></p><p class="headingAnchor" id="H1779067163"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Axel Grothey, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2022; 40:1231.</a></li><li class="breakAll">FDA unveils a streamlined path for the authorization of tumor profiling tests alongside its latest product action. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585347.htm (Accessed on November 16, 2017).</li><li class="breakAll">Evaluation of automatic class III designation for MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets). Available at: https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN170058.pdf (Accessed on November 16, 2017).</li><li class="breakAll">FDA announces approval, CMS proposes coverage of first breakthrough-designated test to detect extensive number of cancer biomarkers. Available at: https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2017-Press-releases-items/2017-11-30-2.html (Accessed on December 04, 2017).</li><li><a class="nounderline abstract_t">Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12:38.</a></li><li><a class="nounderline abstract_t">de Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007; 25:3224.</a></li><li><a class="nounderline abstract_t">Yeoh C, Chau I, Cunningham D, et al. Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. Clin Colorectal Cancer 2003; 3:102.</a></li><li><a class="nounderline abstract_t">Hejna M, Kornek GV, Raderer M, et al. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br J Cancer 1998; 78:760.</a></li><li><a class="nounderline abstract_t">Townsend AR, Bishnoi S, Broadbridge V, et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol 2013; 36:49.</a></li><li><a class="nounderline abstract_t">Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209.</a></li><li><a class="nounderline abstract_t">Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23:9441.</a></li><li class="breakAll">Overman M, et al. Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142 (abstract). J Clin Oncol 40, 2022 (suppl 16; abstr 3510). Abstract available online at https://meetings.asco.org/abstracts-presentations/208415 (Accessed on September 19, 2022).</li><li><a class="nounderline abstract_t">Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009; 100:266.</a></li><li><a class="nounderline abstract_t">Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2013; 105:1151.</a></li><li><a class="nounderline abstract_t">Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20:5322.</a></li><li><a class="nounderline abstract_t">Chida K, Kawazoe A, Kawazu M, et al. A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. Clin Cancer Res 2021; 27:3714.</a></li><li><a class="nounderline abstract_t">Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372:2509.</a></li><li><a class="nounderline abstract_t">André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 383:2207.</a></li><li><a class="nounderline abstract_t">Le DT, Uram JN, Wang H, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol 2016; 34S:ASCO #103.</a></li><li class="breakAll">US Food and Drug Administration press release. FDA approves first cancer treatment for any solid tumor with a specific genetic feature. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm (Accessed on May 24, 2017).</li><li><a class="nounderline abstract_t">Le DT, Kim TW, Van Cutsem E, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol 2020; 38:11.</a></li><li><a class="nounderline abstract_t">Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357:409.</a></li><li><a class="nounderline abstract_t">Overman MJ, Kopetz S, McDermott RS, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol 2016; 34S: ASCO #3501.</a></li><li><a class="nounderline abstract_t">Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18:1182.</a></li><li><a class="nounderline abstract_t">Overman MJ, Lenz H-J, Andre T, et al. Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142. J Clin Oncol 2022; 40S:ASCO #3510.</a></li><li class="breakAll">OPDIVO (nivolumab) injection, 40 mg/4 mL and 100 mg/10 mL. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125554Orig1s034ltr.pdf (Accessed on August 04, 2017).</li><li><a class="nounderline abstract_t">Colle R, Radzik A, Cohen R, et al. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Eur J Cancer 2021; 144:9.</a></li><li><a class="nounderline abstract_t">Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol 2018; 36:773.</a></li><li><a class="nounderline abstract_t">André T, Lonardi S, Wong KYM, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol 2022; 33:1052.</a></li><li><a class="nounderline abstract_t">Latham A, Srinivasan P, Kemel Y, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol 2019; 37:286.</a></li><li><a class="nounderline abstract_t">Schrock AB, Devoe CE, McWilliams R, et al. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol 2017; 3:1546.</a></li><li><a class="nounderline abstract_t">Parikh AR, He Y, Hong TS, et al. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist 2019; 24:1340.</a></li><li><a class="nounderline abstract_t">Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020; 21:1353.</a></li><li><a class="nounderline abstract_t">Rousseau B, Foote MB, Maron SB, et al. The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors. N Engl J Med 2021; 384:1168.</a></li><li><a class="nounderline abstract_t">Morris VK, Kennedy EB, Baxter NN, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol 2023; 41:678.</a></li><li><a class="nounderline abstract_t">Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol 2015; 33:4023.</a></li><li><a class="nounderline abstract_t">Klute KA, Rothe M, Garrett-Mayer E, et al. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol 2022; 6:e2200191.</a></li><li class="breakAll">Dabrafenib: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s027lbl.pdf (Accessed on September 06, 2023).</li><li class="breakAll">Trametinib: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204114s029lbl.pdf (Accessed on September 06, 2023).</li><li><a class="nounderline abstract_t">Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020; 21:1234.</a></li><li><a class="nounderline abstract_t">Salama AKS, Li S, Macrae ER, et al. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol 2020; 38:3895.</a></li><li><a class="nounderline abstract_t">Yaeger R, Cercek A, O'Reilly EM, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 2015; 21:1313.</a></li><li><a class="nounderline abstract_t">van Geel RMJM, Tabernero J, Elez E, et al. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov 2017; 7:610.</a></li><li><a class="nounderline abstract_t">Corcoran RB, André T, Atreya CE, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov 2018; 8:428.</a></li><li><a class="nounderline abstract_t">Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med 2019; 381:1632.</a></li><li><a class="nounderline abstract_t">Kopetz S, Guthrie KA, Morris VK, et al. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol 2021; 39:285.</a></li><li><a class="nounderline abstract_t">Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol 2021; 39:273.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on October 27, 2021).</li><li class="breakAll">FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation (Accessed on April 09, 2020).</li><li class="breakAll">FDA approval of cetuximab, in combination with encorafenib, for patients with previously treated metastatic colorectal with a BRAF V600E mutation; available online at https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/125084Orig1s279ltr.pdf (Accessed on September 30, 2021).</li><li><a class="nounderline abstract_t">Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117:4623.</a></li><li><a class="nounderline abstract_t">Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell 2018; 33:125.</a></li><li><a class="nounderline abstract_t">Loree JM, Bailey AM, Johnson AM, et al. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst 2018; 110:1409.</a></li><li><a class="nounderline abstract_t">Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer 2018; 124:1358.</a></li><li><a class="nounderline abstract_t">Fujii S, Magliocco AM, Kim J, et al. International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. JCO Precis Oncol 2020; 4:6.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Okamoto W, Kato T, et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med 2021; 27:1899.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Taniguchi H, Ikeda M, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 2020; 26:1859.</a></li><li><a class="nounderline abstract_t">Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol 2023; 24:496.</a></li><li class="breakAll">Tucatinib: US Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf (Accessed on January 23, 2023).</li><li><a class="nounderline abstract_t">Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17:738.</a></li><li><a class="nounderline abstract_t">Sartore-Bianchi A, Lonardi S, Aglietta M, et al. Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. JAMA Oncol 2020; 6:927.</a></li><li><a class="nounderline abstract_t">Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2019; 20:518.</a></li><li class="breakAll">Meric-Bernstam F, Hainsworth J, Bose R, et al. MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors (abstract). J Clin Oncol, 392021 (suppl 15; abstr 3004). Abstract available online at https://meetinglibrary.asco.org/record/196653/abstract (Accessed on June 08, 2021).</li><li><a class="nounderline abstract_t">Gupta R, Meric-Bernstam F, Rothe M, et al. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol 2022; 6:e2200306.</a></li><li><a class="nounderline abstract_t">Singh Raghav KP, Siena S, Takashima A, et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. J Clin Oncol 2023; 41;16S.</a></li><li><a class="nounderline abstract_t">Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 2021; 22:779.</a></li><li><a class="nounderline abstract_t">Yoshino T, Di Bartolomeo M, Raghav K, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun 2023; 14:3332.</a></li><li><a class="nounderline abstract_t">Fakih M, Tu H, Hsu H, et al. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer. Oncologist 2022; 27:663.</a></li><li><a class="nounderline abstract_t">Ciardiello D, Chiarazzo C, Famiglietti V, et al. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM). ESMO Open 2022; 7:100567.</a></li><li><a class="nounderline abstract_t">Awad MM, Liu S, Rybkin II, et al. Acquired Resistance to KRASG12C Inhibition in Cancer. N Engl J Med 2021; 384:2382.</a></li><li><a class="nounderline abstract_t">Amodio V, Yaeger R, Arcella P, et al. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discov 2020; 10:1129.</a></li><li><a class="nounderline abstract_t">Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023; 389:2125.</a></li><li><a class="nounderline abstract_t">Hong DS, Fakih MG, Strickler JH, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020; 383:1207.</a></li><li><a class="nounderline abstract_t">Fakih MG, Kopetz S, Kuboki Y, et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022; 23:115.</a></li><li><a class="nounderline abstract_t">Kuboki Y, Yager R, Fakih MG, et al. Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort. Ann Oncol 2022; 33;7S.</a></li><li><a class="nounderline abstract_t">Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med 2023; 388:44.</a></li><li><a class="nounderline abstract_t">Sacher A, LoRusso P, Patel MR, et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med 2023; 389:710.</a></li><li><a class="nounderline abstract_t">Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol 2022; 23:1261.</a></li><li><a class="nounderline abstract_t">Kato S, Subbiah V, Marchlik E, et al. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res 2017; 23:1988.</a></li><li><a class="nounderline abstract_t">Le Rolle AF, Klempner SJ, Garrett CR, et al. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 2015; 6:28929.</a></li><li><a class="nounderline abstract_t">Kim SY, Oh SO, Kim K, et al. NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines. J Cancer 2018; 9:3032.</a></li><li><a class="nounderline abstract_t">Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476.</a></li><li><a class="nounderline abstract_t">Wulaningsih W, Wardhana A, Watkins J, et al. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. Cochrane Database Syst Rev 2016; 2:CD008593.</a></li><li><a class="nounderline abstract_t">Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229.</a></li><li><a class="nounderline abstract_t">Recchia F, Saggio G, Nuzzo A, et al. Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Cancer 2004; 91:1442.</a></li><li><a class="nounderline abstract_t">Bidard FC, Tournigand C, André T, et al. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol 2009; 20:1042.</a></li><li><a class="nounderline abstract_t">Clarke SJ, Yip S, Brown C, et al. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. Eur J Cancer 2011; 47:1826.</a></li><li><a class="nounderline abstract_t">Yasui H, Muro K, Shimada Y, et al. A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. J Cancer Res Clin Oncol 2015; 141:153.</a></li><li><a class="nounderline abstract_t">Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21:2059.</a></li><li><a class="nounderline abstract_t">Rothenberg ML, Oza AM, Burger B, et al. Final results of a phase III trial of 5-FU/Leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU and leucovorin (abstract). Proc Am Soc Clin Oncol 2003; 22:252a.</a></li><li><a class="nounderline abstract_t">Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19:1720.</a></li><li><a class="nounderline abstract_t">Rossini D, Lonardi S, Antoniotti C, et al. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. Br J Cancer 2021; 124:183.</a></li><li><a class="nounderline abstract_t">Hoff PM, Pazdur R, Lassere Y, et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004; 22:2078.</a></li><li><a class="nounderline abstract_t">Lee JJ, Kim TM, Yu SJ, et al. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. Jpn J Clin Oncol 2004; 34:400.</a></li><li><a class="nounderline abstract_t">Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407.</a></li><li><a class="nounderline abstract_t">Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413.</a></li><li><a class="nounderline abstract_t">Kim GP, Sargent DJ, Mahoney MR, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009; 27:2848.</a></li><li><a class="nounderline abstract_t">Michael M, Hedley D, Oza A, et al. The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. Clin Colorectal Cancer 2002; 2:93.</a></li><li><a class="nounderline abstract_t">Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807.</a></li><li><a class="nounderline abstract_t">Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51:5579.</a></li><li><a class="nounderline abstract_t">Maughan TS, James RD, Kerr DJ, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359:1555.</a></li><li><a class="nounderline abstract_t">Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Ann Oncol 1996; 7:961.</a></li><li><a class="nounderline abstract_t">Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 1998; 16:2943.</a></li><li><a class="nounderline abstract_t">Cortinovis D, Bajetta E, Di Bartolomeo M, et al. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer. Tumori 2004; 90:186.</a></li><li><a class="nounderline abstract_t">Comella P, Casaretti R, Crucitta E, et al. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Br J Cancer 2002; 86:1871.</a></li><li><a class="nounderline abstract_t">Laudani A, Gebbia V, Leonardi V, et al. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma. Anticancer Res 2004; 24:1139.</a></li><li><a class="nounderline abstract_t">Aparicio J, Vicent JM, Maestu I, et al. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Ann Oncol 2003; 14:1121.</a></li><li><a class="nounderline abstract_t">Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26:5326.</a></li><li><a class="nounderline abstract_t">Bekaii-Saab TS, Grothey A, Bendell JC, et al. Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study. J Clin Oncol 2012; 30S:ASCO #535.</a></li><li><a class="nounderline abstract_t">Cartwright TH, Yim YM, Yu E, et al. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology. Clin Colorectal Cancer 2012; 11:238.</a></li><li><a class="nounderline abstract_t">Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14:29.</a></li><li><a class="nounderline abstract_t">Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol 2015; 26:724.</a></li><li><a class="nounderline abstract_t">Bennouna J, Hiret S, Bertaut A, et al. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. JAMA Oncol 2019; 5:83.</a></li><li><a class="nounderline abstract_t">Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99:11393.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30:3499.</a></li><li><a class="nounderline abstract_t">Tabernero J, Van Cutsem E, Lakomý R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50:320.</a></li><li><a class="nounderline abstract_t">Torregrosa C, Pernot S, Vaflard P, et al. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study. Int J Cancer 2022; 151:1978.</a></li><li><a class="nounderline abstract_t">Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16:499.</a></li><li><a class="nounderline abstract_t">Goldstein DA, El-Rayes BF. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer? Oncologist 2015; 20:981.</a></li><li><a class="nounderline abstract_t">Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658.</a></li><li><a class="nounderline abstract_t">Peeters M, Kim TW, Li J, et al. Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT. J Clin Oncol 2016; 34S:ASCO #3538.</a></li><li><a class="nounderline abstract_t">Brulé SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer 2015; 51:1405.</a></li><li><a class="nounderline abstract_t">Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757.</a></li><li><a class="nounderline abstract_t">Au HJ, Karapetis CS, O'Callaghan CJ, et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol 2009; 27:1822.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008; 19:92.</a></li><li><a class="nounderline abstract_t">Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626.</a></li><li><a class="nounderline abstract_t">Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311.</a></li><li><a class="nounderline abstract_t">Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.</a></li><li><a class="nounderline abstract_t">Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:4706.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27:1386.</a></li><li><a class="nounderline abstract_t">Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014; 15:569.</a></li><li><a class="nounderline abstract_t">Price T, Kim TW, Li J, et al. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. Eur J Cancer 2016; 68:51.</a></li><li><a class="nounderline abstract_t">Sakai D, Taniguchi H, Sugimoto N, et al. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). Eur J Cancer 2020; 135:11.</a></li><li><a class="nounderline abstract_t">Snyder LC, Astsaturov I, Weiner LM. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer 2005; 5 Suppl 2:S71.</a></li><li><a class="nounderline abstract_t">Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 2008; 13:113.</a></li><li><a class="nounderline abstract_t">Pfeiffer P, Nielsen D, Bjerregaard J, et al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008; 19:1141.</a></li><li><a class="nounderline abstract_t">Bouchahda M, Macarulla T, Liedo G, et al. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2011; 28 Suppl 1:S253.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s277s280lbl.pdf (Accessed on April 08, 2021).</li><li><a class="nounderline abstract_t">Ciardiello F, Normanno N, Martinelli E, et al. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol 2016; 27:1055.</a></li><li><a class="nounderline abstract_t">Parseghian CM, Sun R, Woods M, et al. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol 2023; 41:460.</a></li><li><a class="nounderline abstract_t">Parseghian CM, Loree JM, Morris VK, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol 2019; 30:243.</a></li><li><a class="nounderline abstract_t">Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486:532.</a></li><li><a class="nounderline abstract_t">Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21:795.</a></li><li><a class="nounderline abstract_t">Napolitano S, De Falco V, Martini G, et al. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2023; 9:966.</a></li><li><a class="nounderline abstract_t">Cremolini C, Rossini D, Dell'Aquila E, et al. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol 2019; 5:343.</a></li><li><a class="nounderline abstract_t">Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med 2022; 28:1612.</a></li><li><a class="nounderline abstract_t">Martinelli E, Martini G, Famiglietti V, et al. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA Oncol 2021; 7:1529.</a></li><li><a class="nounderline abstract_t">Topham JT, O'Callaghan CJ, Feilotter H, et al. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. J Clin Oncol 2023; 41:485.</a></li><li><a class="nounderline abstract_t">Raghav K, Ou FS, Venook AP, et al. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). J Clin Oncol 2023; 41:472.</a></li><li><a class="nounderline abstract_t">Kiss I, Mlcochova J, Bortlicek Z, et al. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. Anticancer Res 2016; 36:4955.</a></li><li><a class="nounderline abstract_t">Wadlow RC, Hezel AF, Abrams TA, et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist 2012; 17:14.</a></li><li><a class="nounderline abstract_t">Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18:221.</a></li><li><a class="nounderline abstract_t">Arena S, Bellosillo B, Siravegna G, et al. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clin Cancer Res 2015; 21:2157.</a></li><li><a class="nounderline abstract_t">Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25:4557.</a></li><li><a class="nounderline abstract_t">Hochster HS, Catalano PJ, O'Dwyer PJ, et al. Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. J Clin Oncol 2018; 36S:ASCO #3504.</a></li><li><a class="nounderline abstract_t">Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev 2015; 41:777.</a></li><li><a class="nounderline abstract_t">Satake H, Kato T, Oba K, et al. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study). Oncologist 2020; 25:e1855.</a></li><li><a class="nounderline abstract_t">Pfeiffer P, Yilmaz M, Möller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 2020; 21:412.</a></li><li><a class="nounderline abstract_t">Prager GW, Taieb J, Fakih M, et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med 2023; 388:1657.</a></li><li class="breakAll">Trifluridine and tipiracil - United States Food and Drug Administration Prescribing Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207981s012lbl.pdf (Accessed on August 02, 2023).</li><li><a class="nounderline abstract_t">Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012; 13:993.</a></li><li><a class="nounderline abstract_t">Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372:1909.</a></li><li><a class="nounderline abstract_t">Xu J, Kim TW, Shen L, et al. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol 2018; 36:350.</a></li><li><a class="nounderline abstract_t">van de Haar J, Ma X, Ooft SN, et al. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. Nat Med 2023; 29:605.</a></li><li><a class="nounderline abstract_t">Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.</a></li><li><a class="nounderline abstract_t">Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16:619.</a></li><li><a class="nounderline abstract_t">Bekaii-Saab TS, Ou FS, Ahn DH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 2019; 20:1070.</a></li><li><a class="nounderline abstract_t">Li J, Qin S, Xu RH, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA 2018; 319:2486.</a></li><li><a class="nounderline abstract_t">Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 2023; 402:41.</a></li><li class="breakAll">DailyMed Drug Information: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on December 25, 2023).</li><li><a class="nounderline abstract_t">Shirley M. Fruquintinib: First Global Approval. Drugs 2018; 78:1757.</a></li><li class="breakAll">National Medical Products Administration http://english.nmpa.gov.cn/ (Accessed on July 10, 2023).</li><li><a class="nounderline abstract_t">Bertocchi P, Aroldi F, Prochilo T, et al. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope? J Chemother 2017; 29:102.</a></li><li><a class="nounderline abstract_t">Mori Y, Nishimura T, Kitano T, et al. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 2010; 79:136.</a></li><li><a class="nounderline abstract_t">Parel M, Ranchon F, Nosbaum A, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol 2014; 15:1.</a></li><li><a class="nounderline abstract_t">Napolitano S, Ciardiello D, De Falco V, et al. Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial. Int J Cancer 2023; 153:1520.</a></li></ol></div><div id="topicVersionRevision">Topic 129349 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175857" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227899" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The continuum of care: a paradigm for the management of metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664470" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12952566" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9743296" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22270106" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051767" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16361649" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16361649" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19165197" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23878352" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25139339" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33926917" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26028255" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33264544" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Programmed death-1 blockade in mismatch repair deficient colorectal cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Programmed death-1 blockade in mismatch repair deficient colorectal cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31725351" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28596308" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nivolumab±ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28734759" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Nivolumab (NIVO)±ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Nivolumab (NIVO)±ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33316636" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29355075" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35764271" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30376427" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28617917" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Genomic Profiling of Small-Bowel Adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31040255" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32919526" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761214" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36252154" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of Metastatic Colorectal Cancer: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26392102" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409971" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409971" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409971" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32818466" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32758030" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25589621" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28363909" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29431699" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566309" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33356422" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33503393" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33503393" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33503393" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33503393" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21456008" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29316426" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29718453" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29338072" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35050726" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34764486" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33020649" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37142372" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37142372" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27108243" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32324210" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30857956" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30857956" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36315917" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33961795" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37286557" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35472176" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35994791" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34161704" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Acquired Resistance to KRASG12C Inhibition in Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32430388" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870968" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32955176" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34919824" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36546659" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37611121" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36108661" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27683183" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26078337" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Identification and characterization of RET fusions in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30210625" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689586" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Systemic therapy for colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26869023" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657227" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15467766" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153116" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21665462" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25106731" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775730" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Final results of a phase III trial of 5-FU/Leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU and leucovorin (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18550577" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33024268" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15169794" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15342667" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9807986" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9807987" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380443" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12453323" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610178" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1913676" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047964" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006748" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738562" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15237580" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085178" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15154638" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12853356" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18854571" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22658457" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168366" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25600568" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30422156" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12177445" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : VEGF-Trap: a VEGF blocker with potent antitumor effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22949147" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140268" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35833561" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25877855" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26265225" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18003960" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Cetuximab for the treatment of colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470858" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25979833" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946061" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : K-ras mutations and benefit from cetuximab in advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19273701" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785764" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316791" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18390971" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15269313" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20921462" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27380959" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24739896" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27716478" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32526634" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336752" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18305055" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18281264" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21053102" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21053102" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27002107" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36351210" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30462160" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722830" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26030179" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37200022" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476968" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35915157" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34382998" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36007218" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36067452" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27630355" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22210091" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22270724" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25623215" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17876013" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26428513" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : TAS-102, a novel antitumor agent: a review of the mechanism of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32666647" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31999946" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37133585" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37133585" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22951287" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25970050" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Randomized trial of TAS-102 for refractory metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29215955" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36864254" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23177514" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25981818" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31262657" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946728" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37331369" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37331369" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30357594" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Fruquintinib: First Global Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30357594" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Fruquintinib: First Global Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28032528" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150228" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24417770" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Hypersensitivity to oxaliplatin: clinical features and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37391938" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
